Engineering antibodies for tumor-selective binding of CD47
Patent Information
- Application Number
- JP2021558655
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-05
- Filing Date
- 2020-04-03
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-04-03
Smart Images

Figure 0007581231000053 
Figure 0007581231000054 
Figure 0007581231000055
Abstract
Description
[Technical field]
[0001] Provided herein are tumor-selective antibodies, pharmaceutical compositions, and methods of use for the treatment of pathological conditions brought about by cells undergoing abnormal proliferation, including hematological oncological conditions, hematological malignancies, lymphoproliferative disorders, B cell disorders, B cell malignancies, and B cell lymphomas.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 USC § 119(e) to U.S. Provisional Application No. 62 / 830,335, filed April 5, 2019, which is incorporated by reference in its entirety.
[0003] Sequence Listing This application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy created on March 26, 2020 is named 298068-309_Sequence_Listing.txt and is 612 kilobytes in size. [Background technology]
[0004] Over the past decade, the use of blockade agents against inhibitory immune checkpoints has been one of the most important advances in anticancer therapy (Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev. 2017 Mar;276(1):5-8). The impressive results obtained with the blockade of CTLA-4 and PD-1 led to the evaluation of several innate immune checkpoints that could be targeted in anticancer therapy, in particular the pathways that regulate macrophage function. Macrophages express SIRPα, which interacts with CD47, a ubiquitously expressed protein that mediates a "don't eat me" signal that functions to inhibit phagocytosis. Expression of CD47 confers resistance to phagocytosis of antibody-bound tumor cells by macrophages. In the absence of CD47 binding to SIRPα, antibodies that can bind to Fc receptors on macrophages can enhance the phagocytosis of these cells. Cancer cells have evolved to hijack this interaction by upregulating the expression of CD47 on their cell surface, thus increasing their chances of counterbalancing pro-phagocytic signals and evading innate immune surveillance (Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017 Mar;276(1):145-164). Thus, blocking the CD47-SIRPα interaction represents a promising therapeutic strategy to activate the phagocytic clearance of tumor cells from the body.Several SIRPα-CD47 blocking agents, including humanized and fully human anti-CD47 antibodies, anti-SIRPα antibodies, soluble SIRPα dimers fused to the Fc portion of human IgG, high-affinity monomeric SIRPα lacking the Fc portion, and camelid-derived monomeric fragments of anti-CD47 antibodies (nanobodies), have shown efficacy in in vitro and preclinical studies against various types of human tumors (Veillette A, Chen A., SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy. Trends in Immunology, 2018, 39(3):173-184). Several SIRPα-CD47 blockers, including CC-90002 (anti-CD47), Forty Seven's anti-CD47 (Hu5F9-G4), and Trillium's SIRPα fusion Fc, have been tested in phase I and phase II clinical trials, respectively (Veillette A, Tang Z. Signaling Regulatory Protein (SIRP)α-CD47 Blockade Joins the Ranks of Immune Checkpoint Inhibition. J Clin Oncol. 2019 Feb 27: JCO190012). These approaches in the clinic are limited by the need for combination therapy (e.g., rituximab), targeting CD47 with high affinity binders, tissue sinks (i.e., the presence of non-tumor cells to which the therapeutic antibody binds reduces the bioavailability of the antibody to tumor cells), and observed hematological toxicities with some clinical molecules (anemia, neutropenia, and / or thrombocytopenia). Importantly, while protein therapeutics are indeed being explored to treat several diseases, biopharmaceutical entities can prompt immune responses involving the production of anti-entity antibodies when administered to subjects resulting in reduced efficacy and / or toxicity. Summary of the Invention
[0005] The present invention is directed to antibodies comprising at least one Fab portion that binds to CD47 with low affinity and at least one Fab portion that binds to CD20 with high affinity, wherein the bispecific antibody selectively binds to CD47 on tumor cells and does not substantially bind to CD47 on normal cells.
[0006] Fab portions described herein that bind CD47 with low affinity generally exhibit an affinity for CD47 between about 0.1 μM and about 25 μM, as measured, for example, by surface plasmon resonance (SPR) as the Kd (dissociation constant). Fab portions described herein that bind CD47 with low affinity exhibit an affinity for CD47 of about 0.25 μM to about 20 μM. Certain preferred embodiments exhibit an affinity for CD47 of about 0.4 μM to about 4.0 μM. Certain embodiments exhibit an affinity for CD47 of about 1 μM to about 3.0 μM. In some embodiments, for example, Fab portions that bind CD47 exhibit an affinity for CD47 that is about 0.1 μM to about 5.0 μM. In some embodiments, the Fab portion that binds CD47 is at about 0.1 μM to about 0.2 μM, 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, 0.9 μM, 1.0 μM, 1.1 μM, 1.2 μM, 1.3 μM, 1.4 μM, 1.5 μM, 1.6 μM, 1.7 μM, 1.8 μM, 1.9 μM, 2.0 μM, 2.1 μM, 2.2 μM, 2.3 μM, 2.4 μM, 2.5 μM, 2.6 μM, 2.7 μM, 2.8 μM, 2.9 μM, 3.0 μM, 3.1 μM, 3.2 μM, 3.3 μM, 3.4 μM, 3.5 μM, 3.6 μM, 3.7 μM, 3.8 μM, 3.9 μM, 4.0 μM, 4.1 μM, 4.2 μM, 4.3 μM, 4.4 μM, 4.5 μM, 4.6 μM, 4.7 μM, 4.8 μM, 4.9 μM, 5.0 μM, 5.1 μM, 5.2 μM, 5.3 μM, 5.4 μM, 5.5 μM, 5.6 μM, 5.7 μM, 5.8 μM, 5.9 μM, 6.0 μM, 6.1 μM, 6.2 μM, 6.3 μM, 6.4 μM, 6.5 μM, 6.6 μM, 6.7 μM, 6.8 μM, 6.9 μM, 7.0 μM, 7. and exhibiting an affinity for CD47 of 5 μM, 2.6 μM, 2.7 μM, 2.8 μM, 2.9 μM, 3.0 μM, 3.1 μM, 3.2 μM, 3.3 μM, 3.4 μM, 3.5 μM, 3.6 μM, 3.7 μM, 3.8 μM, 3.9 μM, 4.0 μM, 4.1 μM, 4.2 μM, 4.3 μM, 4.4 μM, 4.5 μM, 4.6 μM, 4.7 μM, 4.8 μM, 4.9 μM, or about 5.0 μM.
[0007] In some embodiments, the Fab portion that binds CD47 exhibits an affinity for CD47 that is between about 0.2 μM and about 4.0 μM. In further embodiments, the Fab portion that binds CD47 exhibits an affinity for CD47 that is between about 0.5 μM and about 3.5 μM. In further embodiments, the Fab portion that binds CD47 exhibits an affinity for CD47 that is between about 1.0 μM and about 3.0 μM.
[0008] The invention is further directed to antibodies comprising at least one Fab portion that binds CD47 and at least one Fab portion that binds CD20, wherein the Fab portion that binds CD47 exhibits a low affinity for CD47 and the Fab portion that binds CD20 exhibits a high affinity for CD20, the bispecific antibody selectively binds to CD47 on tumor cells and does not substantially bind to CD47 on normal cells, and the antibody activates antibody-dependent cellular phagocytosis of tumor cells expressing CD20.
[0009] The present invention is further directed to antibodies comprising at least one Fab portion that binds CD47 and at least one Fab portion that binds CD20, wherein the Fab portion that binds CD47 exhibits a low affinity for CD47 and the Fab portion that binds CD20 exhibits a high affinity for CD20, the bispecific antibody selectively binds to CD47 on tumor cells and does not substantially bind to CD47 on normal cells, and the antibody mediates complement dependent cytotoxicity (CDC) of tumor cells expressing CD20.
[0010] The present invention is further directed to antibodies comprising at least one Fab portion that binds CD47 and at least one Fab portion that binds CD20, wherein the Fab portion that binds CD47 exhibits a low affinity for CD47 and the Fab portion that binds CD20 exhibits a high affinity for CD20, the bispecific antibody selectively binds to CD47 on tumor cells and does not substantially bind to CD47 on normal cells, and the antibody mediates antibody-dependent cellular cytotoxicity (ADCC) of tumor cells expressing CD20.
[0011] The present invention is further directed to monomeric elements of the IgG1 1+1 heterodimer described herein, comprising specific light chain (LC) and heavy chain (HC) constant regions, driving the production of the IgG1 1+1 heterodimer format. In one embodiment, the anti-CD47 LC constant region that reduces LC mispairing during production comprises SEQ ID NO: 340. In another embodiment, the anti-CD47 HC constant region that ensures Fc heterodimerization during production comprises SEQ ID NO: 342. In another embodiment, the anti-CD20 LC constant region that reduces LC mispairing during production comprises SEQ ID NO: 344. In another embodiment, the anti-CD20 HC constant region that ensures Fc heterodimerization during production comprises SEQ ID NO: 346.
[0012] The present invention is further directed to bispecific antibodies, wherein the Fab portion that binds to CD47 is (i) SEQ ID NO:383, SEQ ID NO:387, SEQ ID NO:389, SEQ ID NO:391, SEQ ID NO:393, SEQ ID NO:395, SEQ ID NO:397, SEQ ID NO:399, SEQ ID NO:401, SEQ ID NO:403, SEQ ID NO:405, SEQ ID NO:407, SEQ ID NO:409, SEQ ID NO:411, SEQ ID NO:413, SEQ ID NO:415, SEQ ID NO:417, SEQ ID NO:419, SEQ ID NO:421, SEQ ID NO:423, SEQ ID NO:425, SEQ ID NO:427, SEQ ID NO:429, SEQ ID NO:431, SEQ ID NO:433, SEQ ID NO:435, SEQ ID NO:437, SEQ ID NO:439, SEQ ID NO:441, SEQ ID NO:443, SEQ ID NO:445, a light chain variable region (VL) selected from the group consisting of SEQ ID NO:447, SEQ ID NO:449, SEQ ID NO:451, SEQ ID NO:453, SEQ ID NO:455, SEQ ID NO:457, SEQ ID NO:459, SEQ ID NO:461, SEQ ID NO:463, SEQ ID NO:465, SEQ ID NO:467, SEQ ID NO:469, SEQ ID NO:471, SEQ ID NO:473, SEQ ID NO:475, SEQ ID NO:477, SEQ ID NO:479, SEQ ID NO:481, SEQ ID NO:483, SEQ ID NO:485, SEQ ID NO:487, SEQ ID NO:489, SEQ ID NO:491, SEQ ID NO:493, SEQ ID NO:495, SEQ ID NO:497, SEQ ID NO:499, SEQ ID NO:501, SEQ ID NO:503, SEQ ID NO:505, SEQ ID NO:507, SEQ ID NO:509, and SEQ ID NO:511; (ii) SEQ ID NO:384, SEQ ID NO:388, SEQ ID NO:390, SEQ ID NO:392, SEQ ID NO:394, SEQ ID NO:396, SEQ ID NO:398, SEQ ID NO:400, SEQ ID NO:402, SEQ ID NO:404, SEQ ID NO:406, SEQ ID NO:408, SEQ ID NO:410, SEQ ID NO:412, SEQ ID NO:414, SEQ ID NO:416, SEQ ID NO:418, SEQ ID NO:420, SEQ ID NO:422, SEQ ID NO:424, SEQ ID NO:426, SEQ ID NO:428, SEQ ID NO:430, SEQ ID NO:432, SEQ ID NO:434, SEQ ID NO:436, SEQ ID NO:438, SEQ ID NO:440, SEQ ID NO:442, SEQ ID NO:444, SEQ ID NO:446, SEQ ID NO:448, SEQ ID NO:450, SEQ ID NO:45 and a heavy chain variable region (VH) region selected from the group consisting of SEQ ID NO:2, SEQ ID NO:454, SEQ ID NO:456, SEQ ID NO:458, SEQ ID NO:460, SEQ ID NO:462, SEQ ID NO:464, SEQ ID NO:466, SEQ ID NO:468, SEQ ID NO:470, SEQ ID NO:472, SEQ ID NO:474, SEQ ID NO:476, SEQ ID NO:478, SEQ ID NO:480, SEQ ID NO:482, SEQ ID NO:484, SEQ ID NO:486, SEQ ID NO:488, SEQ ID NO:490, SEQ ID NO:492, SEQ ID NO:494, SEQ ID NO:496, SEQ ID NO:498, SEQ ID NO:500, SEQ ID NO:502, SEQ ID NO:504, SEQ ID NO:506, SEQ ID NO:508, SEQ ID NO:510, and SEQ ID NO:512.
[0013] The present invention is further directed to bispecific antibodies, wherein the CD20-binding Fab portion comprises the anti-CD20 VL CDRs RASSSVSYIH (CDRL1: SEQ ID NO: 353), ATSNLAS (CDRL2: SEQ ID NO: 354), QQWTSNPPT (CDRL3: SEQ ID NO: 355), and the VH CDRs SYNMH (CDRH1: SEQ ID NO: 356), AIYPGNGDTSYNQKFKG (CDRH2: SEQ ID NO: 357), STYYGGDWYFNV (CDRH3: SEQ ID NO: 358).
[0014] The present invention is further directed to a bispecific antibody, wherein the Fab portion that binds to CD20 comprises anti-CD20 LC (SEQ ID NO: 331) and anti-CD20 HC (SEQ ID NO: 332).
[0015] The present invention is further directed to bispecific antibodies, wherein the Fab portion that binds CD47 comprises a light chain variable region (VL) that comprises the VL CDRs RASQGISSWLA (CDRL1: SEQ ID NO: 377), AASVLES (CDRL2: SEQ ID NO: 378), and QQANSFPYT (CDRL3: SEQ ID NO: 379), and a heavy chain variable region (VH) that comprises the VH CDRs NFVMS (CDRH1: SEQ ID NO: 380), TISGSGGSTYYADSVKG (CDRH2: SEQ ID NO: 381), HYILRYFD (CDRH3: SEQ ID NO: 382).
[0016] The present invention is further directed to a bispecific antibody, wherein the Fab portion that binds CD47 comprises a VL (SEQ ID NO:383) and a VH (SEQ ID NO:384).
[0017] Additionally, the present invention is directed to a pharmaceutical composition for inhibiting tumor cells, for administration to a patient in need thereof, comprising a bispecific entity as described herein.
[0018] In addition, the present invention is directed to a pharmaceutical composition for treating a B cell disorder or B cell malignancy, for administration to a patient in need thereof, comprising a bispecific entity as described herein.
[0019] The present invention is further directed to a method of inhibiting tumor cells, comprising administering to a patient in need thereof an effective amount of a bispecific entity described herein.
[0020] Furthermore, the present invention is directed to a method of treating a B cell disorder or B cell malignancy, comprising administering to a patient in need thereof an effective amount of a bispecific entity described herein. [Brief description of the drawings]
[0021] [Figure 1]1 is a schematic diagram of certain attributes of the bispecific entities described herein. The bispecific entities are engineered to overcome the challenges of ubiquitous CD47 expression, including low affinity binding without avidity to CD47, minimal binding to normal cells (i.e., no tissue sink), and high affinity selective avidity binding to CD20 resulting in selective binding to tumor cells. TAA: Tumor Associated Antigen [Diagram 2] Examples of the architecture, protein engineering features, and some biopharmaceutical attributes of bispecific entities are presented. [Figure 3A] 3A-3B show that bispecific entities of the exemplary types described herein induce macrophage-mediated phagocytosis of CD20+ CD47+ OCI-Ly3 NHL cells. (FIG. 3A-B) Graph showing percentage of phagocytic macrophages in view of antibody concentration. (FIG. 3C) Table showing KD and EC50 values of bispecific species described herein. [Figure 3B] 3A-3B show that bispecific entities of the exemplary types described herein induce macrophage-mediated phagocytosis of CD20+ CD47+ OCI-Ly3 NHL cells. (FIG. 3A-B) Graph showing percentage of phagocytic macrophages in view of antibody concentration. (FIG. 3C) Table showing KD and EC50 values of bispecific species described herein. [Figure 3C] 3A-3B show that bispecific entities of the exemplary types described herein induce macrophage-mediated phagocytosis of CD20+ CD47+ OCI-Ly3 NHL cells. (FIG. 3A-B) Graph showing percentage of phagocytic macrophages in view of antibody concentration. (FIG. 3C) Table showing KD and EC50 values of bispecific species described herein. [Figure 4A] FIG. 4 shows an exemplary bispecific entity described herein, where the CD47×CD20 IgG1 species exhibits CDC function. (FIG. 4A-B) Graphs showing CDC in view of antibody concentration. (FIG. 4C) Table showing the mean EC50 values of TPP-1360, TPP-1362, and Rituximab. [Figure 4B]FIG. 4 shows an exemplary bispecific entity described herein, where the CD47×CD20 IgG1 species exhibits CDC function. (FIG. 4A-B) Graphs showing CDC in view of antibody concentration. (FIG. 4C) Table showing the mean EC50 values of TPP-1360, TPP-1362, and Rituximab. [Figure 4C] FIG. 4 shows an exemplary bispecific entity described herein, where the CD47×CD20 IgG1 species exhibits CDC function. (FIG. 4A-B) Graphs showing CDC in view of antibody concentration. (FIG. 4C) Table showing the mean EC50 values of TPP-1360, TPP-1362, and Rituximab. [Figure 5A] 5A-5B show that an exemplary bispecific entity, CD47xCD20 IgG1 species, described herein, exhibits potent ADCC function (i.e., significantly higher than rituximab) in high CD20 NHL cells. (FIG. 5A-5B) Graphs showing cytotoxicity in light of antibody concentration. (FIG. 5C) Table showing CD20 / CD47 ratios. [Figure 5B] 5A-5B show that an exemplary bispecific entity, CD47xCD20 IgG1 species, described herein, exhibits potent ADCC function (i.e., significantly higher than rituximab) in high CD20 NHL cells. (FIG. 5A-5B) Graphs showing cytotoxicity in light of antibody concentration. (FIG. 5C) Table showing CD20 / CD47 ratios. [Figure 5C] 5A-5B show that an exemplary bispecific entity, CD47xCD20 IgG1 species, described herein, exhibits potent ADCC function (i.e., significantly higher than rituximab) in high CD20 NHL cells. (FIG. 5A-5B) Graphs showing cytotoxicity in light of antibody concentration. (FIG. 5C) Table showing CD20 / CD47 ratios. [Figure 6] 1 illustrates exemplary architectures of the bispecific entities described herein, as well as features of specific examples. [Figure 7]TPP-1360, an example of a bispecific entity type described herein, is shown to substantially shift the binding signal to B cells, and weakly to T cells, monocytes, and NK cells, with minimal or no binding to platelets or red blood cells, compared to the binding of TPP-23 (having 408_437 Fab (VL: SEQ ID NO: 899, VH: SEQ ID NO: 900) IgG1), thereby demonstrating selective binding to B cells in human whole blood. [Figure 8] An example of a bispecific species described herein, TPP-1360, is shown and demonstrated to selectively bind to CD47+ / CD20+ Raji cells but not to CD47+ / CD20- human red blood cells (RBCs). [Figure 9] We show that in co-cultures of Raji cells and human RBCs, TPP-1360, an exemplary type of bispecific entity described herein, exhibits dose-dependent binding to CD47+ / CD20+ Raji cells, but no binding to human RBCs, even at concentrations as high as 1 mg / mL. [Figure 10] We show that TPP-1360, for example, potently and completely blocked binding of recombinant human SIRPα-Fc to human CD47 expressed on the surface of the CD20+ / CD47+ lymphoma cell line OCI-Ly3. [Figure 11] We show that TPP-1360, for example, potently and completely blocked recombinant human SIRPα-Fc binding to human CD47 expressed on the surface of the CD20+ / CD47+ lymphoma cell line Raji. [Figure 12] We show that treatment with TPP-1360, for example, induced macrophage-mediated phagocytosis of the CD20+ malignant B cell line Raji. [Figure 13] We show that treatment with TPP-1360, for example, induced macrophage-mediated phagocytosis of the CD20+ malignant B cell line OCI-Ly3. [Figure 14] We show that treatment with TPP-1360, for example, induced macrophage-mediated phagocytosis of the CD20+ malignant B cell line REC-1. [Figure 15]We show that treatment with TPP-1360, for example, induced macrophage-mediated phagocytosis of the CD20+ malignant B cell line RIVA. [Figure 16] For example, we show that treatment with TPP-1360 caused significantly more efficient phagocytosis than rituximab in Raji and OCI-Ly3 cells, likely due to the simultaneous blockade of SIRPα-CD47 interactions by TPP-1360 and engagement of activating receptors such as FcγR. [Figure 17] For example, binding of bispecific antibodies such as Rituxan and TPP-1360 to Raji cells (CD20+ / CD47+) as measured by surface plasmon resonance (SPR) is shown. [Figure 18] FIG. 1 shows the EpiMatrix antibody immunogenicity scale. [Figure 19] 1 shows treatment with TPP-1362 and Rituxan in a Raji xenograft model. [Figure 20] 1 shows treatment with TPP-1360 and Rituxan in a Raji xenograft model. [Figure 21] We show that TPP-1360 and TPP-1362 potently and completely blocked the binding of recombinant human SIRPα to human CD47 expressed on the surface of the CD20+ / CD47+ lymphoma cell line OCI-Ly3, for example. Rituxan was found to have no effect on SIRPα binding. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications and patents referenced herein are incorporated by reference.
[0023] As used herein, the articles "a" and "an" may refer to one or to more than one (eg, to at least one) of the grammatical object of the article.
[0024] As used herein, "about" may generally refer to an acceptable degree of error for the quantity measured given the nature or precision of the measurement. An example of the degree of error is within 5% of a given value or range of values.
[0025] An embodiment described in this specification as "comprising" one or more features may also be considered to disclose the corresponding embodiment "consisting of" and / or "consisting essentially of" such features.
[0026] As used herein, "low affinity for CD47" refers to an affinity for CD47 of less than about 25 μM (e.g., about 0.05 μM to about 25 μM) when measured in vitro as Kd by SPR.
[0027] As used herein, "high affinity for CD20" refers to an affinity for CD20 of about 0.4 nM or more (e.g., about 0.4 nM to about 12 nM). In some embodiments, "high affinity for CD20" refers to an affinity for CD20 of about 0.4 nM to about 5 nM. The bispecific entities described herein selectively bind to CD47 on tumor cells and do not substantially bind to CD47 on normal cells. As used herein, "does not substantially bind to CD47" generally refers to binding of less than 5% of CD47 on (CD20- / CD47+) normal cells. The bispecific entities described herein bind to less than 2% of CD47 on (CD20- / +CD47) normal cells. See Example 7. In other words, the entities described herein generally exhibit 95% or more binding to (CD20+ / CD47+) cells. The entities described herein exhibit greater than 98% binding to (CD20+ / CD47+) cells.
[0028] As used herein, the term "pharmaceutical acceptable" refers to approved by a federal or state regulatory agency or listed in the United States Pharmacopoeia, the European Pharmacopoeia, or other generally recognized pharmacopoeias for use in animals, and more specifically, in humans.
[0029] Concentrations, amounts, volumes, percentages, and other numerical values may be presented herein in a range format, with the understanding that such range formats are used merely for convenience and brevity and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also all individual numerical values or subranges encompassed within the range as if each numerical value and subrange were explicitly recited.
[0030] Minor variations in the amino acid sequences of the antibodies of the invention are contemplated as being encompassed by the present invention, provided that the variations in amino acid sequence maintain at least 75%, at least 80%, at least 90%, at least 95%, or at least 98% or 99% sequence homology or identity to the sequences of the antibodies or antigen-binding fragments thereof provided anywhere herein.
[0031] The antibody of the present invention may comprise variants in which the amino acid residue from one species is replaced with the corresponding residue in another species, either at conserved or non-conserved positions.In one embodiment, the amino acid residue at non-conserved position is replaced with a conserved or non-conserved residue.In particular, conservative amino acid substitutions are contemplated.
[0032] As used herein, "conservative amino acid substitution" refers to an amino acid residue that is replaced with an amino acid residue that has a similar side chain. Families of amino acid residues that have similar side chains are defined in the art and include basic side chains (e.g., lysine, arginine, or histidine), acidic side chains (e.g., aspartic acid, or glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, or cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, or histidine). Thus, when an amino acid of a polypeptide is replaced with another amino acid of the same side chain family, the amino acid substitution is considered to be conservative. The inclusion of conservatively modified variants in the antibodies of the invention does not exclude other forms of variants, such as polymorphic variants, interspecies homologs, and alleles.
[0033] As used herein, "non-conservative amino acid substitutions" include those in which (i) a residue having an electropositive side chain (e.g., arginine, histidine, or lysine) is replaced with or substituted by an electronegative residue (e.g., glutamic acid or aspartic acid); (ii) a hydrophilic residue (e.g., serine or threonine) is replaced with or substituted by a hydrophobic residue (e.g., alanine, leucine, isoleucine, phenylalanine, or valine); (iii) a cysteine or proline is replaced with or substituted by any other residue; or (iv) a residue having a bulky hydrophobic or aromatic side chain (e.g., valine, histidine, isoleucine, or tryptophan) is replaced with or substituted by a residue having a smaller side chain (e.g., alanine, or serine) or no side chain (e.g., glycine).
[0034] The terms "antibody" and "antibodies", as used herein, refer to conventional isotype and monospecific formats as well as multivalent antibodies, including, but not limited to, current bispecific entity formats known in the art as well as bispecific antibodies (including, but not limited to, formats described elsewhere herein).
[0035] A typical antibody comprises at least two "light chains" (LC) and two "heavy chains" (HC). The light and heavy chains of such antibodies are polypeptides consisting of several domains. Each heavy chain comprises a heavy chain variable region (abbreviated herein as "VH") and a heavy chain constant region (abbreviated herein as "CH"). The heavy chain constant region comprises heavy chain constant domains CH1, CH2, and CH3 (antibody classes IgA, IgD, and IgG), and optionally a heavy chain constant domain CH4 (antibody classes IgE and IgM). Each light chain comprises a light chain variable domain (abbreviated herein as "VL") and a light chain constant domain (abbreviated herein as "CL"). The variable regions VH and VL can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The "constant domains" of the heavy and light chains are not directly involved in binding the antibody to a target, but exhibit various effector functions.
[0036] The binding between an antibody and its target antigen or epitope is mediated by complementarity determining regions (CDRs). CDRs are regions of high sequence variability and are located in the variable regions of the heavy and light chains of an antibody that form the antigen binding site. CDRs are the main determinants of antigen specificity. Typically, the heavy and light chains of an antibody each contain three CDRs arranged non-contiguously. The CDR3 regions of the heavy and light chains of an antibody play a particularly important role in the binding specificity / affinity of the antibody according to the invention, and therefore provide a further aspect of the invention.
[0037] Thus, the term "antigen-binding fragment" as used herein includes any naturally occurring or artificially constructed configuration of an antigen-binding polypeptide comprising one, two, or three light chain CDRs and / or one, two, or three heavy chain CDRs, wherein the polypeptide is capable of binding to an antigen.
[0038] The sequences of the CDRs can be identified by reference to any numbering system known in the art, such as the Kabat system (Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)), the Chothia system (Chothia &,Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins," J. Mol. Biol. 196, 901-917 (1987)), or the IMGT system (Lefranc et al., "IMGT Unique Numbering for Immunoglobulin and Cell Receptor Variable Domains and Ig superfamily V-like domains," Dev. Comp. Immunol. 27, 55-77 (2003)). The CDRs shown herein use the boundaries (i.e., sizes) according to Kabat. The numbering of antibody constant region positions described and referred to herein is generally according to Kabat, however, the numbering of the anti-CD47 VL and VH regions (i.e., the antibody residue positions and substitution positions) described herein begins with the N-terminal residue of each variable region (i.e., VL or VH, respectively, with particular reference to SEQ ID NO:325 and SEQ ID NO:326).
[0039] "Bispecific entities as described herein" generally refer to functionally defined antibodies, bispecific element formats, element sequences, antibodies, and antibody species as described herein.
[0040] The term "Fab portion" or "arm" as used herein refers to an antigen-binding fragment of an antibody (i.e., the region of the antibody that binds to an antigen). As used herein, it contains one variable domain of each of the light and heavy chains (VL / VH).
[0041] A "Fab' fragment" contains a single light chain and a single heavy chain, whereas a "Fab' fragment" contains, in addition to CH1 and VH, the region of the heavy chain between the CH1 and CH2 domains required for interchain disulfide bond formation. Thus, two "Fab' fragments" can associate through disulfide bond formation to form a F(ab')2 molecule.
[0042] A "F(ab')2 fragment" contains two light chains and two heavy chains, each of which contains a portion of the constant region necessary for interchain disulfide bond formation between the two heavy chains.
[0043] An "Fv fragment" contains only the variable regions of the heavy and light chains. It does not contain the constant regions.
[0044] A "single domain antibody" is an antibody fragment comprising a single antibody domain unit (eg VH or VL).
[0045] A "single-chain Fv" ("scFv") is an antibody fragment that contains the VH and VL domains of an antibody linked together to form a single chain. A polypeptide linker is generally used to connect the VH and VL domains of an scFv.
[0046] "Tandem scFvs," also known as TandAbs®, are single-chain Fv molecules formed by the covalent association of two scFvs in a tandem orientation with a flexible peptide linker.
[0047] "Bispecific T cell engagers" (BiTEs®) are fusion proteins consisting of two single-chain variable fragments (scFvs) on a single peptide chain. One scFv binds to T cells via the CD3 receptor, and the other binds to an antigen on tumor cells.
[0048] "Diabodies" are small, bivalent, bispecific antibody fragments that contain a heavy chain variable domain (VH) connected to a light chain variable domain (VL) on the same polypeptide chain (VH-VL), connected by a peptide linker that is too short to allow pairing between the two domains on the same chain (Kipriyanov, Int. J. Cancer 77 (1998), 763-772). This forces pairing with complementary domains on another chain and promotes the assembly of a dimeric molecule with two functional antigen-binding sites.
[0049] "DARPins" are bispecific ankyrin repeat molecules. DARPins are derived from the natural ankyrin protein, which can be found in the human genome and is one of the most abundant types of binding proteins. The DARPin library modules are defined by the protein sequences of the natural ankyrin repeats, using 229 ankyrin repeats for the initial design and another 2200 ankyrin repeats for the subsequent refinement. The modules serve as building blocks of the DARPin library. The library modules resemble the human genome sequence. DARPins are composed of 4-6 modules. Each module is about 3.5 kDa, so the average size of a DARPin is 16-21 kDa. The selection of binders is performed by ribosome display, is completely cell-free, and is described in He M.and Taussig MJ.,Biochem Soc Trans.2007,Nov;35(Pt 5):962-5.
[0050] The terms "tumor" and "tumor cell" as used herein broadly refer to cancer cells, including, but not limited to, cells undergoing abnormal proliferation, hematologic neoplastic conditions, hematologic malignancies, lymphoproliferative disorders, B cell disorders, B cell malignancies, and B cell lymphomas.
[0051] As used herein, IgG1 or IgG1 1+1 heterodimeric format essentially refers to a whole IgG1 antibody, (i) consisting of one heavy chain (HC) and one light chain (LC) from one source (i.e., anti-CD47) and the other consisting of one heavy chain (HC) and one light chain (LC) from another source (e.g., anti-CD20). See, e.g., Figures 2 and 6.
[0052] CD47 The value of cancer immunotherapy targeting the CD47 / SIRPα axis is well established. See, for example, Weiskopf, K., et al., Eur J Cancer. 2017 May; 76: 100; Feng, M., et al., Nat Rev Cancer. 2019 Oct; 19(10): 568-586. Anti-CD47 approaches in the clinic have been limited by the need for combination therapy, tissue sinks targeting CD47 with high affinity binders, immunogenicity, and hematological toxicity (anemia, neutropenia, and / or thrombocytopenia) with some clinical molecules observed.
[0053] CD47 is upregulated on tumor cells, but is also ubiquitously expressed on all cells, including NK cells, RBCs, and platelets, at relatively high levels. Thus, monospecific agents targeting CD47 tend to exhibit poor pharmacokinetic properties due to target-mediated drug elimination (TMDD) and side effects, including anemia and thrombocytopenia. Target-mediated drug elimination (TMDD) is a phenomenon in which a drug affects its pharmacokinetic properties by binding with high affinity to its pharmacological target site (such as a receptor). Anti-CD47 IgG4 mAb is generally required to reduce toxicity. Thus, the drug activity of a single anti-CD47 (e.g., IgG1) tends to be limited.
[0054] Russ, A., et al., Blood Rev. 2018 Nov;32(6):480, described a specific, well-characterized IgG4 anti-CD47 antibody (CC-90002). See in particular WO2013 / 119714 (US Patent No. 9,045,541). Various amino acid substitutions in this antibody have been described and are designed to increase cell-free production and reduce immunogenicity. See WO2016 / 109415 (US2017 / 0369572), WO2018 / 009499 (US2019 / 0241654), and WO2018 / 183182. CC-90002 is a high affinity IgG4 P / E anti-CD47 molecule that binds to CD47 expressed in diseased and normal tissues.
[0055] However, because CD47 is widely expressed on normal tissues and tumor cells, high affinity anti-CD47 antibodies may result in undesirable toxicity. Thus, bispecific antibodies comprising a CD47 binding domain that improves CC-90002 in terms of toxicity and efficacy are provided herein. In particular, the bispecific entities described herein selectively and safely target tumor cells that have little or no binding to CD47 in peripheral tissues. The present invention is directed to an antibody comprising at least one Fab portion that binds to CD47 and at least one Fab portion that binds to CD20, wherein the Fab portion that binds to CD47 exhibits low affinity for CD47 (e.g., Kd of greater than 100 nM) and the Fab portion that binds to CD20 exhibits high affinity for CD20 (e.g., Kd of less than 5 nM), and the bispecific antibody selectively binds to CD47 on tumor cells and does not substantially bind to CD47 on normal cells.
[0056] CC-90002 is provided as a reference parent sequence and as a source of anti-CD47 elements for the construction of some of the bispecific entities described herein. The CC-90002 VL CDRs are SEQ ID NO: 347 (CDRL1), SEQ ID NO: 348 (CDRL2), and SEQ ID NO: 349 (CDRL3). The CC-90002 VH CDRs are SEQ ID NO: 350 (CDRH1), SEQ ID NO: 351 (CDRH2), and SEQ ID NO: 352 (CDRH3). For reference, the VL (SEQ ID NO: 325) and VH (SEQ ID NO: 326) of CC-90002 are also provided. For reference, the CC-90002 VL fused to the native IgG1 LC constant region to form the whole LC is provided as CC-90002 whole LC / IgG1 (SEQ ID NO: 327). For reference, the CC-90002 VH fused to the native IgG1 HC constant region to form the entire HC is provided as CC-90002 entire HC / IgG1 (SEQ ID NO: 328).
[0057] Both the VH and VL regions of CC-90002 were engineered to reduce immunogenicity while retaining functionality for use in the bispecific entities described herein.
[0058] The anti-CD47 arm for the bispecific entities described herein was also derived from CL-4033, as described in Example 2 and elsewhere herein.
[0059] The bispecific entities described and exemplified herein are demonstrated to overcome the challenges of, for example, single agent anti-CD47 mAb therapy. Due to their detuned affinity for CD47, the CD47×CD20 bispecific entities described and provided herein inhibit CD20 + It preferentially binds to tumor-associated antigen (TAA) cells, thereby inhibiting CD47 +Cell-mediated sink effects and off-target tumor toxicity are reduced. Taken together, the cell potency, in vivo efficacy, and safety data indicate that the CD47xCD20 bispecifics described and exemplified herein offer a unique option, for example, as single agents for CD20-positive B-cell malignancies.
[0060] FIG. 1 is a schematic diagram of the specific attributes of the bispecific entities described herein, which have been engineered to overcome the challenges of ubiquitous CD47 expression, including low affinity binding without avidity to CD47, minimal binding to normal cells (i.e., no tissue sink), and high affinity selective avidity binding to the tumor-associated antigen (TAA) CD20, resulting in selective binding to tumor cells.
[0061] The CD47xCD20 bispecifics provided herein may comprise CD20 binding domains from any high affinity CD20 binder. The LC (SEQ ID NO: 329) and HC (SEQ ID NO: 330) of rituximab are the preferred source of anti-CD20 elements for the construction of the bispecific entities described herein. In certain embodiments, the bispecific antibodies provided herein comprise one or both of the VL (SEQ ID NO: 323) and VH (SEQ ID NO: 324) of rituximab, or comprise the VL CDRs of rituximab: SEQ ID NO: 353 (CDRL1), SEQ ID NO: 354 (CDRL2), and SEQ ID NO: 355 (CDRL3), and the VH CDRs of rituximab: SEQ ID NO: 356 (CDRH1), SEQ ID NO: 357 (CDRH2), and SEQ ID NO: 358 (CDRH3), respectively. The constant regions of the anti-CD20 IgG1 LC and HC described elsewhere herein are fused to the carboxy terminus of the rituximab VL (SEQ ID NO: 323) and rituximab VH (SEQ ID NO: 324), respectively. The anti-CD20 LC (SEQ ID NO: 331) is preferred for use in constructing the bispecific entities of the invention. The anti-CD20 HC (SEQ ID NO: 332) is preferred for use in constructing the bispecific entities of the invention.
[0062] The exemplary bispecific entities described herein do not substantially bind to CD47 in peripheral tissues, RBCs, and platelets, selectively and safely target CD20+ tumor cells, provide extended half-life with lower toxicity, and the antibodies mediate complement-dependent cytotoxicity (CDC) of tumor cells.
[0063] The bispecific entity is preferably in an IgG1 1+1 heterodimeric format. In certain embodiments, the bispecific antibodies provided herein comprise two antigen-binding arms that are covalently linked to form a single entity. IgG bispecific antibodies using two Fab domains require careful consideration of expression and purification strategies to ensure proper assembly of the desired product. Efforts can be made at the genetic level to bias the expression of the desired bispecific antibody. For example, substitutions in the CH3 domain of IgG Fc have been described to drive Fc heterodimerization. Additionally, the knob-in-hole strategy utilizes steric hindrance to generate a complementary asymmetric molecular face between two different Fc CH3 domains. Other strategies known in the art use electrostatic complementarity to drive specificity. Alternatively, a wild-type IgG scaffold can be used, and the resulting product combinations can be separated during protein purification to isolate the desired product.
[0064] The preferred bispecific antibody of the present invention is essentially a natural human IgG1 antibody, consisting of (A) one anti-CD47 IgG1 (monomer) portion, including one entire light chain (LC) and one entire heavy chain (HC), and (B) one anti-CD20 IgG1 (monomer) portion, including one entire light chain (LC) and one entire heavy chain (HC). The two monomers form a conventional dimeric IgG1 antibody, with one arm (Fab1) providing attenuated binding of CD47 and the other arm (Fab2) providing affinity binding and avidity for CD20. Figures 2 and 6 show exemplary architectures and exemplary protein engineering features of CD47×CD20 described herein.
[0065] Preferred monomer elements of the IgG1 1+1 heterodimer described herein each contain specific sequences within the LC and HC constant regions to reduce homodimer formation during production of the IgG1 1+1 heterodimer format. In one embodiment, the anti-CD47 LC constant region to ensure proper LC / HC pairing during production comprises SEQ ID NO: 340. In another embodiment, the anti-CD47 HC constant region to ensure Fc heterodimer formation during production comprises SEQ ID NO: 342. A preferred anti-CD20 LC constant region to ensure proper LC / HC pairing during production comprises SEQ ID NO: 344. A preferred anti-CD20 HC constant region to ensure Fc heterodimer formation during production comprises SEQ ID NO: 346. An exemplary anti-CD47 LC constant region to ensure proper LC / HC pairing during production is SEQ ID NO: 339. An exemplary anti-CD47 HC constant region to ensure Fc heterodimer formation during production is SEQ ID NO: 341. An exemplary anti-CD20 LC constant region to ensure proper LC / HC pairing during production is SEQ ID NO: 343. An exemplary anti-CD20 HC constant region to ensure Fc heterodimer formation during production is SEQ ID NO: 345.
[0066] A preferred IgG1 constant region for use with the 161 Fabs described herein is an IgG1 1+1 heterodimer format, with the Fab providing attenuated binding of CD47 having the LC constant region SEQ ID NO: 339 and the HC constant region SEQ ID NO: 341. The anti-CD47 IgG1 LC constant region containing substitutions Q124E, L135W, Q160E, and T180E ensures proper LC / HC pairing during production of the IgG1 1+1 heterodimeric format compared to CC-90002.
[0067] Further provided herein is a preferred anti-CD47 IgG1 LC constant region (SEQ ID NO: 339). In certain embodiments (e.g., certain embodiments of the bispecific antibodies provided herein), the anti-CD47 VL region provided herein is fused to the amino terminus of SEQ ID NO: 339. SEQ ID NO: 340 is internal to SEQ ID NO: 339. SEQ ID NO: 339 and SEQ ID NO: 440 contain substitutions Q124E, L135W, Q160E, and T180E that ensure proper LC / HC pairing during production of the IgG1 1+1 heterodimeric format.
[0068] An anti-CD47 IgG1 HC constant region is provided that contains substitutions Q179K, T371V, T389L, K420L, and T422W to ensure proper LC / HC pairing and Fc heterodimerization during production of the IgG1 1+1 heterodimer format.
[0069] Further provided herein is a preferred anti-CD47 IgG1 HC constant region (SEQ ID NO: 341). In certain embodiments (e.g., certain embodiments of the bispecific antibodies provided herein), the anti-CD47 VH region provided herein is fused to the amino terminus of SEQ ID NO: 341. SEQ ID NO: 342 is internal to SEQ ID NO: 341. SEQ ID NO: 341 and SEQ ID NO: 342 contain substitutions Q179K, T371V, T389L, K420L, and T422W to ensure Fc heterodimer formation during production of the IgG1 1+1 heterodimer format.
[0070] An anti-CD20 IgG1 LC constant region is provided which, compared to rituximab, contains the substitutions F116A, Q124R, L135V, T178R which ensure proper LC / HC pairing during production of the IgG1 1+1 heterodimeric format.
[0071] Further provided herein is a preferred anti-CD20 IgG1 LC constant region (SEQ ID NO: 343). In certain embodiments (e.g., certain embodiments of the bispecific antibodies provided herein), the anti-CD20 VL region provided herein is fused to the amino terminus of SEQ ID NO: 343. SEQ ID NO: 344 is internal to SEQ ID NO: 343. SEQ ID NO: 343 and SEQ ID NO: 344 contain substitutions F116A, Q124R, L135V, and T178R that reduce homodimer formation during production of the IgG1 1+1 heterodimeric format.
[0072] An anti-CD20 IgG1 HC constant region is provided that, compared to rituximab, contains substitutions A139W, L143E, K145T, Q179E, T371V, L372Y, F436A, and Y438V that ensure Fc heterodimer formation during production of the IgG1 1+1 heterodimer format.
[0073] Further provided herein is a preferred anti-CD20 IgG1 HC constant region (SEQ ID NO: 345). In certain embodiments (e.g., certain embodiments of the bispecific antibodies provided herein), the anti-CD20 VH region provided herein is fused to the amino terminus of SEQ ID NO: 345. SEQ ID NO: 346 is internal to SEQ ID NO: 345. SEQ ID NO: 345 and SEQ ID NO: 346 contain substitutions A139W, L143E, K145T, Q179E, T371V, L372Y, F436A, and Y438V that reduce homodimer formation during production of the IgG1 1+1 heterodimeric format.
[0074] CD47×CD20 bispecific A CD47xCD20 bispecific program was initiated to identify therapeutic antibodies capable of blocking human CD47 binding to SIRPα only on CD20-expressing cells. Examples derived from that project and provided herein exhibit detuned affinity for CD47 while binding with high affinity to CD20. Upon binding to CD20 on tumor cells, the antibodies, via the IgG1 Fc, potently block the CD47-SIRPα interaction and the co-engagement activating receptor FcγR on effector cells, resulting in activation of macrophage-mediated phagocytosis and natural killer (NK) cell-mediated cytotoxicity against tumor cells.
[0075] I. Bispecific antibodies containing anti-CD47 derived from CC-90002 CD47 epitope mapping and CC-90002 The anti-CD47 epitope was determined by solving the crystal structure of the non-deregulated parental version of CC-90002 (408_437) Fab (CC-90002 VL: SEQ ID NO: 899, CC-90002 VH: SEQ ID NO: 900) in complex with the human CD47 extracellular domain at 2.4 Å resolution. The three light chain (LC) CDRs (SEQ ID NO: 347, SEQ ID NO: 348, SEQ ID NO: 349), as well as the heavy chain (HC) CDR2 (SEQ ID NO: 351) and HC CDR3 (SEQ ID NO: 352) are all involved in binding to the large surface area of the CD47 ECD. The HC CDRs make multiple contacts with the KGRD loop of CD47 and the LC CDRs overlap with the SIRPα binding site, explaining the ability of CC-90002 and the bispecific entities described herein to block SIRPα binding.
[0076] The CD47×CD20 bispecific entities described herein are + / CD20 -It is designed to facilitate CD20-restricted blockade of the CD47-SIRPα "don't eat me" signal on cancer cells expressing both CD20 and CD47, while sparing normal cells. Multiple steps of protein engineering led to the bispecific anti-CD47 Fab described herein. (1) Protein engineering was used on both the VH and VL chains of CC-90002 to reduce immunogenicity while retaining functionality, and (2) protein engineering was also used to deregulate CC-90002. The CD47 and CD20 targeting IgG1 bispecific antibodies with reduced affinity for CD47 described and exemplified herein 1) retain efficacy in mediating anti-tumor function by targeting the CD47-SIRPα interaction and engaging the activating receptor FcγR, 2) minimize the target-mediated sink effect and toxicity observed with anti-CD47 therapeutics, and 3) incorporate CD47 and CD20 engagement into a single molecule, avoiding the need for combination therapy with two monoclonal antibodies.
[0077] Protein Design The crystal structure of the effector antigen, CD47, led to the construction of an in silico library of Fab variants that bound to a high affinity anti-CD47 Fab (CC-90002 (408_437VL: SEQ ID NO: 899, 408_437VH: SEQ ID NO: 900)) predicted to have a range of lower affinity, better stability, and less immunogenicity. Variants from this library were expressed as IgG1 bispecifics with a high affinity anti-CD20 Fab (Rituximab (VL: SEQ ID NO: 323, CC-90002 VH: SEQ ID NO: 324)).
[0078] The resulting 143 physical constructs were screened for selectivity and potency using cell-based assays for CD47 binding and SIRPα blockade to identify variants that effectively bind the effector antigen CD47 on target cells co-expressing the selector antigen CD20, but minimally bind to non-target cell lines expressing only the effector antigen CD47.
[0079] Examples of anti-CD47 whole LC and HC, LC and HC constant regions, VL and VH regions, and CDR sequences with substantially reduced binding affinity to CD47 and reduced immunogenicity compared to CC-90002, including but not limited to the IgG1 isotype, are provided herein and described elsewhere. The IgG1 1+1 heterodimeric format preferably comprises (A) one anti-CD47 IgG1 (monomeric) portion comprising one whole light chain (LC) and one whole heavy chain (HC), and (B) one anti-CD20 IgG1 (monomeric) portion comprising one whole light chain (LC) and one whole heavy chain (HC), as described below.
[0080] The antibodies of the invention comprise VL and VH amino acid sequences derived from CC-90002 (i.e., SEQ ID NO: 325 and SEQ ID NO: 326), respectively, and have substantially attenuated binding affinity to CD47, i.e., the Fab portion that binds to CD47 exhibits low affinity. It was found that the various affinities for CD47 from the screen of deregulated anti-CD47 binders described herein dramatically reduced binding to non-target cells, yet still avidly bind effectively to CD47 once recruited to the surface of target cells after binding to CD20. Initial deregulated CD47×CD20 bispecific leads achieved this selectivity with affinities ranging from about 0.5 μM to about 2.5 μM (FIGS. 3A-3C). TPP-1360, for example, was measured to have an affinity of 1.7 μM for human CD47 ECD, reflecting an affinity reduction of about 350-fold compared to the parent anti-CD47 binders. TPP-1362 was measured to have an affinity for human CD47 ECD with a Kd of 0.796 μM, reflecting an approximately 150-fold decrease in affinity compared to the parent anti-CD47 binder. The deregulated CD47×CD20 bispecific entities described herein exhibit selectivity with affinities ranging from about 0.2 μM to about 4 μM.
[0081] The bispecific entities described herein selectively bind CD47 on tumor cells expressing CD20 and do not substantially bind CD47 on normal cells. The ratio of binding to Raji (CD47+CD20+) versus human RBCs in a co-culture binding assay for the bispecific entities described herein is, for example, about 6000-fold. The ratio of binding to human B cells (CD47+CD20+) versus human RBCs for the bispecific entities described herein is, for example, about 700-fold. The level of selectivity of the bispecific entities described herein ranges from about 400- to about 8,000-fold selectivity depending on the expression levels of CD20 and CD47 in tumor and normal cells. Thus, assuming a fixed level of CD47 expression, the bispecific entities described herein exhibit increased selectivity and potency as CD20 levels increase.
[0082] Exemplary antibodies of the invention also comprise VL and VH regions (i.e., SEQ ID NO:325 and SEQ ID NO:326), respectively, derived from CC-90002, where the VL, VH, or both sequences contain one or more amino acid substitutions that substantially reduce the immunogenicity of the resulting antibody. Exemplary antibodies of the invention also comprise VL and VH regions (i.e., SEQ ID NO:325 and SEQ ID NO:326), respectively, derived from CC-90002, where the VL, VH, or both sequences contain one or more amino acid substitutions that reduce the binding affinity of the resulting antibody to CD47 and substantially reduce the immunogenicity of the resulting antibody.
[0083] Thus, preferred antibodies derived from CC-90002 described herein exhibit 1-7 amino acid substitutions relative to VL SEQ ID NO:325 and 1-11 amino acid substitutions relative to VH SEQ ID NO:326.
[0084] Additionally, antibodies derived from CC-90002 are contemplated herein and functionally described separately, and exhibit 8 amino acid substitutions relative to VL SEQ ID NO: 325. Additionally, antibodies derived from CC-90002 are contemplated herein and functionally described separately, and exhibit 9 amino acid substitutions relative to VL SEQ ID NO: 325. Additionally, antibodies derived from CC-90002 are contemplated herein and functionally described separately, and exhibit 10 amino acid substitutions relative to VL SEQ ID NO: 325.
[0085] Additionally, antibodies derived from CC-90002 are contemplated herein and functionally described separately, and exhibit 12 amino acid substitutions relative to VH SEQ ID NO: 326. Additionally, antibodies derived from CC-90002 are contemplated herein and functionally described separately, and exhibit 13 amino acid substitutions relative to VH SEQ ID NO: 326. Additionally, antibodies derived from CC-90002 are contemplated herein and functionally described separately, and exhibit 14 amino acid substitutions relative to VH SEQ ID NO: 326.
[0086] Provided herein is a CD47 antibody, wherein the anti-CD47 VL exhibits one to seven amino acid substitutions relative to SEQ ID NO:325, at least one of which is selected from the group consisting of A10S, M11L, K24R, A51E, N52S, L54F, and S56D, and the anti-CD47 VH exhibits one to 11 amino acid substitutions relative to SEQ ID NO:326, at least one of which is selected from the group consisting of T14P, Q43K, A44G, E59Y, D66G, M76T, S84R, S88A, M93V, S102E, and T115L.
[0087] Also provided herein is a CD47 antibody, wherein the anti-CD47 VL exhibits at least one, at least two, at least three, at least four, at least five, at least six, or at least seven amino acid substitutions relative to SEQ ID NO:325, wherein the amino acid substitutions are selected from the group consisting of A10S, M11L, K24R, A51E, N52S, L54F, and S56D.
[0088] The present invention is directed to an antibody as described herein, wherein the anti-CD47 VL exhibits at least seven amino acid substitutions relative to SEQ ID NO:325, seven of which are A10S, M11L, K24R, A51E, N52S, L54F, and S56D.
[0089] The present invention is directed to an antibody as described herein, wherein the anti-CD47 VH exhibits at least one, two, three, four, five, six, seven, eight, nine, ten, or eleven amino acid substitutions relative to SEQ ID NO: 326, wherein the amino acid substitutions are selected from the group consisting of T14P, Q43K, A44G, E59Y, D66G, M76T, S84R, S88A, M93V, S102E, and T115L.
[0090] The present invention is directed to an antibody as described herein, wherein the anti-CD47 VH exhibits at least 11 amino acid substitutions relative to SEQ ID NO:326, 11 of which are T14P, Q43K, A44G, E59Y, D66G, M76T, S84R, S88A, M93V, S102E, and T115L.
[0091] The anti-CD47 LC (SEQ ID NO:335) and HC (SEQ ID NO:336) are the preferred source of anti-CD47 elements for constructing the bispecific entities described herein, in particular the VL (SEQ ID NO:319) and VH (SEQ ID NO:320) comprising the VL CDRs: SEQ ID NO:365 (CDRL1), SEQ ID NO:366 (CDRL2), and SEQ ID NO:367 (CDRL3), and the VH CDRs: SEQ ID NO:368 (CDRH1), SEQ ID NO:369 (CDRH2), and SEQ ID NO:370 (CDRH3), respectively. The substitutions A10S, M11L, K24R, A51E, N52S, L54F, and S56D are key VL (SEQ ID NO:319) substitutions for CC-90002, resulting in lower CD47 binding affinity and reduced immunogenicity. T14P, Q43K, A44G, E59Y, D66G, M76T, S84R, S88A, M93V, S102E, and T115L are important VH (SEQ ID NO: 320) for CC-90002, resulting in low CD47 binding affinity (especially E59Y and S102E) and reduced immunogenicity. The constant regions of the LC and HC of anti-CD47 IgG1 described elsewhere herein (e.g., SEQ ID NO: 339 and SEQ ID NO: 341, respectively) are fused to the carboxy terminus of the VL (SEQ ID NO: 319) and VH (SEQ ID NO: 320) in certain embodiments. Anti-CD47 LC (SEQ ID NO: 335) is preferably used in the construction of the bispecific entity of the invention. Anti-CD47 HC (SEQ ID NO: 336) is preferably used in the construction of the bispecific entity of the invention. Substitutions Q124E, L135W, Q160E, and T180E are positions in SEQ ID NO: 335 that are important for ensuring proper LC / HC pairing during production of an IgG1 1+1 heterodimer format. Substitutions Q179K, T371V, T389L, K420L, and T422W are positions in SEQ ID NO: 336 that are important for reducing the tendency for homodimer formation during production of an IgG1 1+1 heterodimer format.
[0092] The invention is further directed to an antibody as described elsewhere herein, wherein the anti-CD47 VL exhibits one to three amino acid substitutions relative to SEQ ID NO: 325, and wherein at least one, at least two, or at least three amino acid substitutions in the anti-CD47 VL (SEQ ID NO: 325) are selected from the group consisting of A10S, M11L, and K24R (e.g., SEQ ID NO: 321), and the anti-CD47 VH exhibits one to 11 amino acid substitutions relative to SEQ ID NO: 326, and wherein at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or at least eleven amino acid substitutions in the anti-CD47 VH (SEQ ID NO: 326) are selected from the group consisting of T14P, Q43K, A44G, E59Y, D66G, M76T, S84R, S88A, M93V, S102E, and T115L (e.g., SEQ ID NO: 322).
[0093] The present invention is particularly directed to antibodies as described elsewhere herein, wherein the anti-CD47 VH exhibits one to eleven amino acid substitutions relative to SEQ ID NO: 326, and wherein at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or at least eleven amino acid substitutions in the anti-CD47 VH (SEQ ID NO: 326) are selected from the group consisting of T14P, Q43K, A44G, E59Y, D66G, M76T, S84R, S88A, M93V, S102E, and T115L (e.g., SEQ ID NO: 322).
[0094] The anti-CD47 LC (SEQ ID NO:337) and HC (SEQ ID NO:338) are the preferred source of anti-CD47 elements for the construction of the bispecific entities described herein, in particular the VL (SEQ ID NO:321) and VH (SEQ ID NO:322) comprising the VL CDRs: SEQ ID NO:371, SEQ ID NO:372, and SEQ ID NO:373, and the VH CDRs: SEQ ID NO:374, SEQ ID NO:375, and SEQ ID NO:376, respectively. A10S, M11L, and K24R are key VL (SEQ ID NO:321) positions for conferring low CD47 binding affinity and reducing immunogenicity. Substitutions T14P, Q43K, A44G, E59Y, D66G, M76T, S84R, S88A, M93V, S102E, and T115L are key VH (SEQ ID NO: 322) positions that result in low CD47 binding affinity (especially E59Y and S102E) and reduced immunogenicity. The constant regions of the LC and HC of anti-CD47 IgG1 (e.g. SEQ ID NO: 339 and SEQ ID NO: 341, respectively) are fused to the carboxy termini of the VL (SEQ ID NO: 321) and VH (SEQ ID NO: 322). Anti-CD47 LC (SEQ ID NO: 337) is preferably used in the construction of bispecific entities of the invention. Anti-CD47 HC (SEQ ID NO: 338) is preferably used in the construction of bispecific entities of the invention. Substitutions Q124E, L135W, Q160E, and T180E are key positions in SEQ ID NO: 337 for reducing the tendency for homodimer formation during production of an IgG1 1+1 heterodimer format. Substitutions Q179K, T371V, T389L, K420L, and T422W are key positions in SEQ ID NO: 338 for reducing the tendency for homodimer formation during production of an IgG1 1+1 heterodimer format.
[0095] The present invention is particularly directed to antibodies as described elsewhere herein, wherein the anti-CD47 VL exhibits 1-10 amino acid substitutions relative to SEQ ID NO: 325, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid substitutions in the anti-CD47 VL (SEQ ID NO: 325) are selected from the group consisting of A10S, M11L, K24Q, K39D, K42T, K45Q, A51E, N52S, L54F, and S56D (e.g., SEQ ID NO: 317), and the anti-CD47 VH exhibits 1-11 amino acid substitutions relative to SEQ ID NO: 326, and wherein the anti-CD47 At least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or at least eleven amino acid substitutions in VH (SEQ ID NO:326) are selected from the group consisting of T14P, A44G, E59Y, D66G, M76T, S84A, R87T, S88A, M93V, S102E, and T115L (e.g., SEQ ID NO:318).
[0096] The present invention is particularly directed to antibodies as described elsewhere herein, wherein the anti-CD47 VH exhibits between 1 and 11 amino acid substitutions relative to SEQ ID NO: 326, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or at least 11 amino acid substitutions in the anti-CD47 VH (SEQ ID NO: 326) are selected from the group consisting of T14P, A44G, E59Y, D66G, M76T, S84A, R87T, S88A, M93V, S102E, and T115L (e.g., SEQ ID NO: 318).
[0097] The anti-CD47 LC (SEQ ID NO: 333) and HC (SEQ ID NO: 334) are the preferred source of anti-CD47 elements for the construction of the bispecific entities described herein, in particular the VL (SEQ ID NO: 317) and VH (SEQ ID NO: 318) comprising the VL CDRs: SEQ ID NO: 359, SEQ ID NO: 360, and SEQ ID NO: 361, and the VH CDRs: SEQ ID NO: 362, SEQ ID NO: 363, and SEQ ID NO: 364, respectively. The substitutions A10S, M11L, K24Q, K39D, K42T, K45Q, A51E, N52S, L54F, and S56D are key VL positions (SEQ ID NO: 317) for conferring low CD47 binding affinity and reducing immunogenicity. Substitutions T14P, A44G, E59Y, D66G, M76T, S84A, R87T, S88A, M93V, S102E, and T115L are key VH (SEQ ID NO: 318) positions that result in low CD47 binding affinity (especially E59Y and S102E) and reduced immunogenicity. The constant regions of the LC and HC of anti-CD47 IgG1 (e.g., SEQ ID NO: 339 and SEQ ID NO: 341, respectively) are fused to the carboxy terminus of the VL (SEQ ID NO: 317) and VH (SEQ ID NO: 318). Anti-CD47 LC (SEQ ID NO: 333) is preferably used in the construction of bispecific entities of the invention. Anti-CD47 HC (SEQ ID NO: 334) is preferably used in the construction of bispecific entities of the invention. Substitutions Q124E, L135W, Q160E and T180E are key positions in SEQ ID NO: 333 for reducing the tendency for homodimer formation during production of an IgG1 1+1 heterodimer format. Substitutions Q179K, T371V, T389L, K420L and T422W are key positions in SEQ ID NO: 334 for reducing the tendency for homodimer formation during production of an IgG1 1+1 heterodimer format.
[0098] Exemplary antibodies described and contemplated herein include anti-CD20 VL CDRs RASSSVSYIH (SEQ ID NO: 353), ATSNLAS (SEQ ID NO: 354), and QQWTSNPPT (SEQ ID NO: 355), and VH CDRs SYNMH (SEQ ID NO: 356), AIYPGNGDTSYNQKFKG (SEQ ID NO: 357), and STYYGGDWYFNV (SEQ ID NO: 358). An exemplary bispecific antibody described elsewhere herein includes anti-CD20 VL (SEQ ID NO: 323) and VH (SEQ ID NO: 324). An example of a preferred type of bispecific antibody functionally described herein includes anti-CD20 LC (SEQ ID NO: 331) and anti-CD20 HC (SEQ ID NO: 332).
[0099] 161 cases of deconditioned anti-CD47 VL / VH Fab derived from CC-90002 Further provided herein are 161 VL and VH Fabs derived from parent antibody CC-90002. For each of the 161 Fabs, the VL amino acid sequences are provided as odd-numbered SEQ ID NOs: 1-321, and the VH amino acid derived sequences are provided as even-numbered SEQ ID NOs: 2-322. The identified Fabs (VL / VH pairs) are each numbered as a pair of adjacent SEQ ID NOs (i.e., disclosed herein according to the following pattern): SEQ ID NO: 1 / SEQ ID NO: 2, SEQ ID NO: 3 / SEQ ID NO: 4, etc., through SEQ ID NO: 321 / SEQ ID NO: 322.
[0100] SEQ ID NO:1 / SEQ ID NO:2, SEQ ID NO:3 / SEQ ID NO:4, SEQ ID NO:5 / SEQ ID NO:6, SEQ ID NO:7 / SEQ ID NO:8, SEQ ID NO:9 / SEQ ID NO:10, SEQ ID NO:11 / SEQ ID NO:12, SEQ ID NO:13 / SEQ ID NO:14, SEQ ID NO:15 / SEQ ID NO:16, SEQ ID NO:17 / SEQ ID NO:18, SEQ ID NO:19 / SEQ ID NO:20, SEQ ID NO:21 / SEQ ID NO:22, SEQ ID NO:23 / SEQ ID NO:24, SEQ ID NO:25 / SEQ ID NO:26, SEQ ID NO:27 / SEQ ID NO:28, SEQ ID NO:29 / SEQ ID NO:30, SEQ ID NO:31 / SEQ ID NO:32, SEQ ID NO:33 / SEQ ID NO:34, SEQ ID NO:35 / SEQ ID NO:36, SEQ ID NO:37 / SEQ ID NO:38, SEQ ID NO:39 / SEQ ID NO:40, SEQ ID NO:41 / SEQ ID NO:42, SEQ ID NO:43 / SEQ ID NO:44, SEQ ID NO:45 / SEQ ID NO:46, SEQ ID NO:47 / SEQ ID NO:48, SEQ ID NO:49 / SEQ ID NO:50, SEQ ID NO:51 / SEQ ID NO:52, SEQ ID NO:53 / SEQ ID NO:54, SEQ ID NO:55 / SEQ ID NO:56, SEQ ID NO:57 / SEQ ID NO:58, SEQ ID NO:59 / SEQ ID NO:60, SEQ ID NO:61 / SEQ ID NO:62, SEQ ID NO:63 / SEQ ID NO:64, SEQ ID NO:65 / SEQ ID NO:66, SEQ ID NO:67 / SEQ ID NO:68, SEQ ID NO:69 / SEQ ID NO:70, SEQ ID NO:71 / SEQ ID NO:72, No. 73 / SEQ ID NO: 74, SEQ ID NO: 75 / SEQ ID NO: 76, SEQ ID NO: 77 / SEQ ID NO: 78, SEQ ID NO: 79 / SEQ ID NO: 80, SEQ ID NO: 81 / SEQ ID NO: 82, SEQ ID NO: 83 / SEQ ID NO: 84, SEQ ID NO: 85 / SEQ ID NO: 86, SEQ ID NO: 87 / SEQ ID NO: 88, SEQ ID NO: 89 / SEQ ID NO: 90, SEQ ID NO: 91 / SEQ ID NO: 92, SEQ ID NO: 93 / SEQ ID NO: 94, SEQ ID NO: 95 / SEQ ID NO: 96, SEQ ID NO: 97 / SEQ ID NO: 98, SEQ ID NO: 99 / SEQ ID NO: 100, SEQ ID NO: 101 / SEQ ID NO: 102, SEQ ID NO: 103 / SEQ ID NO: 104, SEQ ID NO: 105 / SEQ ID NO: 106, SEQ ID NO: 107 / SEQ ID NO:108, SEQ ID NO:109 / SEQ ID NO:110, SEQ ID NO:111 / SEQ ID NO:112, SEQ ID NO:113 / SEQ ID NO:114, SEQ ID NO:115 / SEQ ID NO:116, SEQ ID NO:117 / SEQ ID NO:118, SEQ ID NO:119 / SEQ ID NO:120, SEQ ID NO:121 / SEQ ID NO:122, SEQ ID NO:123 / SEQ ID NO:124, SEQ ID NO:125 / SEQ ID NO:126, SEQ ID NO:127 / SEQ ID NO:128, SEQ ID NO:129 / SEQ ID NO:130, SEQ ID NO:131 / SEQ ID NO:132, SEQ ID NO:133 / SEQ ID NO:134, SEQ ID NO:135 / SEQ ID NO:136, SEQ ID NO:137 / SEQ ID NO:138,SEQ ID NO:139 / SEQ ID NO:140, SEQ ID NO:141 / SEQ ID NO:142, SEQ ID NO:143 / SEQ ID NO:144, SEQ ID NO:145 / SEQ ID NO:146, SEQ ID NO:147 / SEQ ID NO:148, SEQ ID NO:149 / SEQ ID NO:150, SEQ ID NO:151 / SEQ ID NO:152, SEQ ID NO:153 / SEQ ID NO:154, SEQ ID NO:155 / SEQ ID NO:156, SEQ ID NO:157 / SEQ ID NO:158, SEQ ID NO:159 / SEQ ID NO:160, SEQ ID NO:161 / SEQ ID NO:162, SEQ ID NO:163 / SEQ ID NO:164, SEQ ID NO:165 / SEQ ID NO:166, SEQ ID NO:167 / SEQ ID NO:168, SEQ ID NO:169 / SEQ ID NO:170, SEQ ID NO:171 / SEQ ID NO:172, SEQ ID NO:173 / SEQ ID NO:174, SEQ ID NO:175 / SEQ ID NO:176, SEQ ID NO:177 / SEQ ID NO:178, SEQ ID NO:179 / SEQ ID NO:180, SEQ ID NO:181 / SEQ ID NO:182, SEQ ID NO:183 / SEQ ID NO:184, SEQ ID NO:185 / SEQ ID NO:186, SEQ ID NO:187 / SEQ ID NO:188, SEQ ID NO:189 / SEQ ID NO:190, SEQ ID NO:191 / SEQ ID NO:192, SEQ ID NO:193 / SEQ ID NO:194, SEQ ID NO:195 / SEQ ID NO:196, SEQ ID NO:197 / SEQ ID NO:198, SEQ ID NO:199 / SEQ ID NO:200, SEQ ID NO:201 / SEQ ID NO:202, SEQ ID NO:203 / SEQ ID NO:204, SEQ ID NO:205 / SEQ ID NO:206, SEQ ID NO:207 / SEQ ID NO:208, SEQ ID NO:209 / SEQ ID NO:210, SEQ ID NO:211 / SEQ ID NO:212, SEQ ID NO:213 / SEQ ID NO:214, SEQ ID NO:215 / SEQ ID NO:216, SEQ ID NO:217 / SEQ ID NO:218, SEQ ID NO:219 / SEQ ID NO:220, SEQ ID NO:221 / SEQ ID NO:222, SEQ ID NO:223 / SEQ ID NO:224, SEQ ID NO:225 / SEQ ID NO:226, SEQ ID NO:227 / SEQ ID NO:228, SEQ ID NO:229 / SEQ ID NO:230, SEQ ID NO:231 / SEQ ID NO:232, SEQ ID NO:233 / SEQ ID NO:234, SEQ ID NO:235 / SEQ ID NO:236, SEQ ID NO:237 / SEQ ID NO:238, SEQ ID NO:239 / SEQ ID NO:240, SEQ ID NO:241 / SEQ ID NO:242; SEQ ID NO:243 / SEQ ID NO:244, SEQ ID NO:245 / SEQ ID NO:246, SEQ ID NO:247 / SEQ ID NO:248, SEQ ID NO:249 / SEQ ID NO:250, SEQ ID NO:251 / SEQ ID NO:252, SEQ ID NO:253 / SEQ ID NO:254, SEQ ID NO:255 / SEQ ID NO:256, SEQ ID NO:257 / SEQ ID NO:258, SEQ ID NO:259 / SEQ ID NO:260, SEQ ID NO:261 / SEQ ID NO:262,SEQ ID NO:263 / SEQ ID NO:264, SEQ ID NO:265 / SEQ ID NO:266, SEQ ID NO:267 / SEQ ID NO:268, SEQ ID NO:269 / SEQ ID NO:270, SEQ ID NO:271 / SEQ ID NO:272, SEQ ID NO:273 / SEQ ID NO:274, SEQ ID NO:275 / SEQ ID NO:276, SEQ ID NO:277 / SEQ ID NO:278, SEQ ID NO:279 / SEQ ID NO:280, SEQ ID NO:281 / SEQ ID NO:282, SEQ ID NO:283 / SEQ ID NO:284, SEQ ID NO:285 / SEQ ID NO:286, SEQ ID NO:287 / SEQ ID NO:288, SEQ ID NO:289 / SEQ ID NO:290, SEQ ID NO:291 / SEQ ID NO: Column number 292, SEQ ID NO: 293 / SEQ ID NO: 294, SEQ ID NO: 295 / SEQ ID NO: 296, SEQ ID NO: 297 / SEQ ID NO: 298, SEQ ID NO: 299 / SEQ ID NO: 300, SEQ ID NO: 301 / SEQ ID NO: 302, SEQ ID NO: 303 / SEQ ID NO: 304, SEQ ID NO: 305 / SEQ ID NO: 306, SEQ ID NO: 307 / SEQ ID NO: 308, SEQ ID NO: 309 / SEQ ID NO: 310, SEQ ID NO: 311 / SEQ ID NO: 312, SEQ ID NO: 315 / SEQ ID NO: 316, SEQ ID NO: 317 / SEQ ID NO: 318, SEQ ID NO: 319 / SEQ ID NO: 320, and SEQ ID NO: 321 / SEQ ID NO: 322.
[0101] While each pair shown is preferred in its own right, the disclosure is not limited thereto. The population of VL and VH domain species disclosed herein can be used to form separate pairs, i.e., diverse Fabs selected from the population of VL and VH domain species provided.
[0102] Exemplary antibodies are provided that are functionally described elsewhere herein, the anti-CD47 VL being SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO: 69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:121, SEQ ID NO:123, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:1 33, SEQ ID NO:135, SEQ ID NO:137, SEQ ID NO:139, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:145, SEQ ID NO:147, SEQ ID NO:149, SEQ ID NO:151, SEQ ID NO:153, SEQ ID NO:155, SEQ ID NO:157, SEQ ID NO:159, SEQ ID NO:161, SEQ ID NO:163, SEQ ID NO:165, SEQ ID NO:167, SEQ ID NO:169, SEQ ID NO:171, SEQ ID NO:173, SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:179, SEQ ID NO:181, SEQ ID NO:183, SEQ ID NO:185, SEQ ID NO:187, SEQ ID NO:189, SEQ ID NO:191, SEQ ID NO:19 3, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:211, SEQ ID NO:213, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:219, SEQ ID NO:221, SEQ ID NO:223, SEQ ID NO:225, SEQ ID NO:227, SEQ ID NO:229, SEQ ID NO:231, SEQ ID NO:233, SEQ ID NO:235, SEQ ID NO:237, SEQ ID NO:239, SEQ ID NO:241, SEQ ID NO:243, SEQ ID NO:245, SEQ ID NO:247, SEQ ID NO:249, SEQ ID NO:251, SEQ ID NO:253,and selected from the group consisting of SEQ ID NO:255, SEQ ID NO:257, SEQ ID NO:259, SEQ ID NO:261, SEQ ID NO:263, SEQ ID NO:265, SEQ ID NO:267, SEQ ID NO:269, SEQ ID NO:271, SEQ ID NO:273, SEQ ID NO:275, SEQ ID NO:277, SEQ ID NO:279, SEQ ID NO:281, SEQ ID NO:283, SEQ ID NO:285, SEQ ID NO:287, SEQ ID NO:289, SEQ ID NO:291, SEQ ID NO:293, SEQ ID NO:295, SEQ ID NO:297, SEQ ID NO:299, SEQ ID NO:301, SEQ ID NO:303, SEQ ID NO:305, SEQ ID NO:307, SEQ ID NO:309, SEQ ID NO:311, SEQ ID NO:313, SEQ ID NO:315, SEQ ID NO:317, SEQ ID NO:319, and SEQ ID NO:321, and anti-CD47 VH is SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156, SEQ ID NO:158, SEQ ID NO:160, SEQ ID NO:162, SEQ ID NO:164, SEQ ID NO:166, SEQ ID NO:168, SEQ ID NO:170, SEQ ID NO:172, SEQ ID NO:174, SEQ ID NO:176, SEQ ID NO:178, SEQ ID NO:180, SEQ ID NO:182, SEQ ID NO:184, SEQ ID NO:186, SEQ ID NO:188,SEQ ID NO:190, SEQ ID NO:192, SEQ ID NO:194, SEQ ID NO:196, SEQ ID NO:198, SEQ ID NO:200, SEQ ID NO:202, SEQ ID NO:204, SEQ ID NO:206, SEQ ID NO:208, SEQ ID NO:210, SEQ ID NO:212, SEQ ID NO:214, SEQ ID NO:216, SEQ ID NO:218, SEQ ID NO:220, SEQ ID NO:222, SEQ ID NO:224, SEQ ID NO:226, SEQ ID NO:228, SEQ ID NO:230, SEQ ID NO:232, SEQ ID NO:234, SEQ ID NO:236, SEQ ID NO:238, SEQ ID NO:240, SEQ ID NO:242, SEQ ID NO:244, SEQ ID NO:246, SEQ ID NO:248, SEQ ID NO:250, SEQ ID NO:252, SEQ ID NO:254, SEQ ID NO:255, No. 258, SEQ ID NO: 260, SEQ ID NO: 262, SEQ ID NO: 264, SEQ ID NO: 266, SEQ ID NO: 268, SEQ ID NO: 270, SEQ ID NO: 272, SEQ ID NO: 274, SEQ ID NO: 276, SEQ ID NO: 278, SEQ ID NO: 280, SEQ ID NO: 282, SEQ ID NO: 284, SEQ ID NO: 286, SEQ ID NO: 288, SEQ ID NO: 290, SEQ ID NO: 292, SEQ ID NO: 294, SEQ ID NO: 296, SEQ ID NO: 298, SEQ ID NO: 300, SEQ ID NO: 302, SEQ ID NO: 304, SEQ ID NO: 306, SEQ ID NO: 308, SEQ ID NO: 310, SEQ ID NO: 312, SEQ ID NO: 314, SEQ ID NO: 316, SEQ ID NO: 318, SEQ ID NO: 320, and SEQ ID NO: 322.
[0103] II. Bispecific antibodies containing anti-CD47 derived from CL-4033 OMT-derived deregulation and CL-4033 OmniRat animals were immunized with the extracellular domain (ECD) of human CD47. OmniRat animals are transgenic animals that express a repertoire of human light and heavy chains such that antibodies produced in response to immunization contain fully human sequences. From this immunization campaign, 37 variants of selected antibodies, within the light chain CDRL2, were generated to reduce their potential immunogenicity. From these 37 variants, 11 were selected for further development based on conservation of function, expressibility, and predicted low immunogenicity. From this list, CL-4033 was selected for deregulation.
[0104] A homology model of CL-4033 was constructed and a library of variants was designed that were predicted to have a range of low affinities for CD47 with good stability and low immunogenicity. The 64 deregulated CL-4033 variants were then paired with the arms of anti-CD20 rituximab using mutations.
[0105] The CD47×CD20 bispecific entities described herein are + / CD20 - It is designed to facilitate blockade of CD20 restriction of the CD47-SIRPα "don't eat me" signal on cancer cells expressing both CD20 and CD47, while sparing normal cells. Multiple steps of protein engineering led to the bispecific anti-CD47 Fab described herein. (1) Protein engineering was used on both the VH and VL chains of CL-4033 to reduce immunogenicity while retaining functionality, and (2) protein engineering was used to down-tune the CD47 binding affinity of CL-4033. The CD47 and CD20 targeting IgG1 bispecific antibodies with reduced affinity for CD47 described and exemplified herein 1) retain efficacy in mediating anti-tumor function by targeting the CD47-SIRPα interaction and engaging the activating receptor FcγR, 2) minimize the target-mediated sink effect and toxicity observed with anti-CD47 therapeutics, and 3) incorporate CD47 and CD20 engagement into a single molecule, avoiding the need for combination therapy with two monoclonal antibodies.
[0106] 64 cases of deconditioned anti-CD47 VL / VH Fab derived from CL-4033 Further provided herein are 64 VL and VH Fab regions derived from parent antibody CL-4033. The VL regions of each of the 64 Fabs are provided as odd-numbered SEQ ID NOs: 383 and 387-511, and the VH regions are provided as even-numbered SEQ ID NOs: 384 and 388-512. The first example Fab (VL / VH pair) is identified as SEQ ID NO: 383 / 384. The further identified Fabs (VL / VH pairs) are each numbered as a pair of adjacent SEQ ID NOs (i.e., disclosed herein according to the following pattern): SEQ ID NO: 387 / SEQ ID NO: 388, SEQ ID NO: 389 / SEQ ID NO: 390, etc., through SEQ ID NO: 503 / SEQ ID NO: 504, SEQ ID NO: 505 / SEQ ID NO: 506, SEQ ID NO: 507 / SEQ ID NO: 508, SEQ ID NO: 509 / SEQ ID NO: 510, SEQ ID NO: 511 / SEQ ID NO: 512.
[0107] SEQ ID NO:387 / SEQ ID NO:388, SEQ ID NO:389 / SEQ ID NO:390, SEQ ID NO:391 / SEQ ID NO:392, SEQ ID NO:393 / SEQ ID NO:394, SEQ ID NO:395 / SEQ ID NO:396, SEQ ID NO:397 / SEQ ID NO:398, SEQ ID NO:399 / SEQ ID NO:400, SEQ ID NO:401 / SEQ ID NO:402, SEQ ID NO:403 / SEQ ID NO:404, SEQ ID NO:405 / SEQ ID NO:406, SEQ ID NO:407 / SEQ ID NO:408, SEQ ID NO:409 / SEQ ID NO:410, SEQ ID NO:411 / SEQ ID NO:412, SEQ ID NO:413 / SEQ ID NO:414, SEQ ID NO:415 / SEQ ID NO:416, SEQ ID NO:417 / SEQ ID NO:418, SEQ ID NO:419 / SEQ ID NO:420, SEQ ID NO:421 / SEQ ID NO:422, SEQ ID NO:423 / SEQ ID NO:424, SEQ ID NO:425 / SEQ ID NO:426, SEQ ID NO:427 / SEQ ID NO:428, SEQ ID NO:429 / SEQ ID NO:430, SEQ ID NO:431 / SEQ ID NO:432, SEQ ID NO:433 / SEQ ID NO:434, SEQ ID NO:435 / SEQ ID NO:436, SEQ ID NO:437 / SEQ ID NO:438, SEQ ID NO:439 / SEQ ID NO:440, SEQ ID NO:441 / SEQ ID NO:442, SEQ ID NO:443 / SEQ ID NO:444, SEQ ID NO:445 / SEQ ID NO:446, SEQ ID NO:447 / SEQ ID NO:448, SEQ ID NO:449 / SEQ ID NO:450, SEQ ID NO:451 / SEQ ID NO:452, SEQ ID NO:453 / SEQ ID NO:454, SEQ ID NO:455 / SEQ ID NO:456, SEQ ID NO:457 / SEQ ID NO:458, SEQ ID NO:459 / SEQ ID NO:460, SEQ ID NO:461 / SEQ ID NO:462, SEQ ID NO:463 / SEQ ID NO:464, SEQ ID NO:465 / SEQ ID NO:466, SEQ ID NO:467 / SEQ ID NO:468, SEQ ID NO:469 / SEQ ID NO:470, SEQ ID NO:471 / SEQ ID NO:472, SEQ ID NO:473 / SEQ ID NO:474, SEQ ID NO:475 / SEQ ID NO:476, SEQ ID NO:477 / SEQ ID NO:478, SEQ ID NO:479 / SEQ ID NO:480, SEQ ID NO:481 / SEQ ID NO:482, SEQ ID NO:483 / SEQ ID NO:484, SEQ ID NO:485 / SEQ ID NO:486, SEQ ID NO:487 / SEQ ID NO:488, SEQ ID NO:489 / SEQ ID NO:490, SEQ ID NO:491 / SEQ ID NO:492, SEQ ID NO:493 / SEQ ID NO:494, SEQ ID NO:495 / SEQ ID NO:496, SEQ ID NO:497 / SEQ ID NO:498, SEQ ID NO:499 / SEQ ID NO:500, SEQ ID NO:501 / SEQ ID NO:502, SEQ ID NO:503 / SEQ ID NO:504, SEQ ID NO:505 / SEQ ID NO:506, SEQ ID NO:507 / SEQ ID NO:508, SEQ ID NO:509 / SEQ ID NO:510,and SEQ ID NO:511 / SEQ ID NO:512.
[0108] The disclosure is not limited to each of the pairs shown, although each pair is preferred in itself. The population of VL and VH domain species disclosed herein can be used to form separate pairs, i.e., diverse Fabs selected from the population of VL and VH domain species provided.
[0109] Exemplary antibodies are provided which are functionally described elsewhere herein, wherein the anti-CD47 VL is selected from the group consisting of SEQ ID NO:383, SEQ ID NO:387, SEQ ID NO:389, SEQ ID NO:391, SEQ ID NO:393, SEQ ID NO:395, SEQ ID NO:397, SEQ ID NO:399, SEQ ID NO:401, SEQ ID NO:403, SEQ ID NO:405, SEQ ID NO:407, SEQ ID NO:409, SEQ ID NO:411, SEQ ID NO:413, SEQ ID NO:415, SEQ ID NO:417, SEQ ID NO:419, SEQ ID NO:421, SEQ ID NO:423, SEQ ID NO:425, SEQ ID NO:427, SEQ ID NO:429, SEQ ID NO:431, SEQ ID NO:433, SEQ ID NO:435, SEQ ID NO:437, SEQ ID NO:439, SEQ ID NO:441, SEQ ID NO:443, SEQ ID NO:445, SEQ ID NO:447, SEQ ID NO:449, SEQ ID NO:451, SEQ ID NO:453, SEQ ID NO:455, SEQ ID NO:457, SEQ ID NO:459, SEQ ID NO:461, SEQ ID NO:463, SEQ ID NO:465, SEQ ID NO:467, SEQ ID NO:469, SEQ ID NO:471, SEQ ID NO:473, SEQ ID NO:475, SEQ ID NO:477, SEQ ID NO:479, SEQ ID NO:481, SEQ ID NO:483, SEQ ID NO:485, SEQ ID NO:487, SEQ ID NO:489, SEQ ID NO:491, SEQ ID NO:493, SEQ ID NO:495, SEQ ID NO:497, SEQ ID NO:499, SEQ ID NO:501, SEQ ID NO:503, SEQ ID NO:505, SEQ ID NO:507, SEQ ID NO:509, SEQ ID NO:511, and anti-CD47VH is SEQ ID NO:384, SEQ ID NO:388, SEQ ID NO:390, SEQ ID NO:392, SEQ ID NO:394, SEQ ID NO:396, SEQ ID NO:398, SEQ ID NO:400, SEQ ID NO:402, SEQ ID NO:404, SEQ ID NO:406, SEQ ID NO:408, SEQ ID NO:410, SEQ ID NO:412, SEQ ID NO:414, SEQ ID NO:416, SEQ ID NO:418, SEQ ID NO:420, SEQ ID NO:422, SEQ ID NO:424, SEQ ID NO:426, SEQ ID NO:428, SEQ ID NO:430, SEQ ID NO:432, SEQ ID NO:434, SEQ ID NO:436, SEQ ID NO:438, SEQ ID NO:440, SEQ ID NO:442, SEQ ID NO:444, SEQ ID NO:446, SEQ ID NO:448, SEQ ID NO:449, SEQ ID NO:500, SEQ ID NO:501, SEQ ID NO:502, SEQ ID NO:503, SEQ ID NO:504, SEQ ID NO:505, SEQ ID NO:506, SEQ ID NO:507, SEQ ID NO:508, SEQ ID NO:509, SEQ ID NO:510, SEQ ID NO:511, SEQ ID NO:512, SEQ ID NO:513, SEQ ID NO:514, SEQ ID NO:515, SEQ ID NO:516, SEQ ID NO:518, SEQ ID NO:520, SEQ ID NO:522, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO 50, SEQ ID NO:452, SEQ ID NO:454, SEQ ID NO:456, SEQ ID NO:458, SEQ ID NO:460, SEQ ID NO:462, SEQ ID NO:464, SEQ ID NO:466, SEQ ID NO:468, SEQ ID NO:470, SEQ ID NO:472, SEQ ID NO:474, SEQ ID NO:476, SEQ ID NO:478, SEQ ID NO:480, SEQ ID NO:482, SEQ ID NO:484, SEQ ID NO:486, SEQ ID NO:488, SEQ ID NO:490, SEQ ID NO:492, SEQ ID NO:494, SEQ ID NO:496, SEQ ID NO:498, SEQ ID NO:500, SEQ ID NO:502, SEQ ID NO:504, SEQ ID NO:506, SEQ ID NO:508, SEQ ID NO:510, and SEQ ID NO:512.
[0110] Exemplary antibodies are also provided, the Fab portion that binds to CD47 being: (i) (SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:379), (SEQ ID NO:513, SEQ ID NO:514, SEQ ID NO:515), (SEQ ID NO:519, SEQ ID NO:520, SEQ ID NO:521), (SEQ ID NO:525, SEQ ID NO:526, SEQ ID NO:527), (SEQ ID NO:531, SEQ ID NO:532, SEQ ID NO:533), (SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:539), (SEQ ID NO:543, SEQ ID NO:544, SEQ ID NO:545), (SEQ ID NO:549, SEQ ID NO:550, SEQ ID NO:551), (SEQ ID NO:552, SEQ ID NO:553, SEQ ID NO:554, SEQ ID NO:555, SEQ ID NO:556), (SEQ ID NO:557, SEQ ID NO:558, SEQ ID NO:559), (SEQ ID NO:560, SEQ ID NO:561), (SEQ ID NO:562, SEQ ID NO:563), (SEQ ID NO:564, SEQ ID NO:565), (SEQ ID NO:566, SEQ ID NO:567), (SEQ ID NO:568, SEQ ID NO:569), (SEQ ID NO:570, SEQ ID NO:571), (SEQ ID NO:572, SEQ ID NO:573), (SEQ ID NO:574, SEQ ID NO:575), (SEQ ID NO:576, SEQ ID NO:577), (SEQ ID NO:578, SEQ ID NO:57 5, SEQ ID NO:556, SEQ ID NO:557), (SEQ ID NO:561, SEQ ID NO:562, SEQ ID NO:563), (SEQ ID NO:567, SEQ ID NO:568, SEQ ID NO:569), (SEQ ID NO:573, SEQ ID NO:574, SEQ ID NO:575), (SEQ ID NO:579, SEQ ID NO:580, SEQ ID NO:581), (SEQ ID NO:585, SEQ ID NO:586, SEQ ID NO:587), (SEQ ID NO:591, SEQ ID NO:592, SEQ ID NO:593), (SEQ ID NO:597, SEQ ID NO:598, SEQ ID NO:599), (SEQ ID NO:603, SEQ ID NO:604, SEQ ID NO:605), (SEQ ID NO:609, SEQ ID NO:610, SEQ ID NO:611), 11), (SEQ ID NO:615, SEQ ID NO:616, SEQ ID NO:617), (SEQ ID NO:621, SEQ ID NO:622, SEQ ID NO:623), (SEQ ID NO:627, SEQ ID NO:628, SEQ ID NO:629), (SEQ ID NO:633, SEQ ID NO:634, SEQ ID NO:635), (SEQ ID NO:639, SEQ ID NO:640, SEQ ID NO:641), (SEQ ID NO:645, SEQ ID NO:646, SEQ ID NO:647), (SEQ ID NO:651, SEQ ID NO:652, SEQ ID NO:653), (SEQ ID NO:657, SEQ ID NO:658, SEQ ID NO:659), (SEQ ID NO:663, SEQ ID NO:664, SEQ ID NO:665), (SEQ ID NO:669, SEQ ID NO:670), (SEQ ID NO:671, SEQ ID NO:672), (SEQ ID NO:673, SEQ ID NO:674, SEQ ID NO:675), (SEQ ID NO:676, SEQ ID NO:677), (SEQ ID NO:678, SEQ ID NO:679), (SEQ ID NO:679, SEQ ID NO:680), (SEQ ID NO:681, SEQ ID NO:682), (SEQ ID NO:683, SEQ ID NO:684, SEQ ID NO:685), (SEQ ID NO:686, SEQ ID NO:687), (SEQ ID NO:688, SEQ ID NO:689, SEQ ID NO:690), (SEQ ID NO:681, SEQ ID NO:682, SEQ ID NO:683), (SEQ ID NO:684, No. 670, SEQ ID NO: 671), (SEQ ID NO: 675, SEQ ID NO: 676, SEQ ID NO: 677), (SEQ ID NO: 681, SEQ ID NO: 682, SEQ ID NO: 683), (SEQ ID NO: 687, SEQ ID NO: 688, SEQ ID NO: 689), (SEQ ID NO: 693, SEQ ID NO: 694, SEQ ID NO: 695), (SEQ ID NO: 699, SEQ ID NO: 700, SEQ ID NO: 701), (SEQ ID NO: 705, SEQ ID NO: 706, SEQ ID NO: 707), (SEQ ID NO: 711, SEQ ID NO: 712, SEQ ID NO: 713), (SEQ ID NO: 717, SEQ ID NO: 718, SEQ ID NO: 719), (SEQ ID NO: 723, SEQ ID NO: 724, SEQ ID NO: 725),(SEQ ID NO:729, SEQ ID NO:730, SEQ ID NO:731), (SEQ ID NO:735, SEQ ID NO:736, SEQ ID NO:737), (SEQ ID NO:741, SEQ ID NO:742, SEQ ID NO:743), (SEQ ID NO:747, SEQ ID NO:748, SEQ ID NO:749), (SEQ ID NO:753, SEQ ID NO:754, SEQ ID NO:755), (SEQ ID NO:759, SEQ ID NO:760, SEQ ID NO:761), (SEQ ID NO:765, SEQ ID NO:766, SEQ ID NO:767), (SEQ ID NO:771, SEQ ID NO:772, SEQ ID NO:773), (SEQ ID NO:777, SEQ ID NO:778, SEQ ID NO:779), (SEQ ID NO:783, SEQ ID NO:784, SEQ ID NO:785), (SEQ ID NO:789, SEQ ID NO:790, SEQ ID NO:791), (SEQ ID NO:795, SEQ ID NO:796, SEQ ID NO:797), (SEQ ID NO:801, SEQ ID NO:802, SEQ ID NO:803), (SEQ ID NO:807, SEQ ID NO:808, SEQ ID NO:809), (SEQ ID NO:8 13, SEQ ID NO: 814, SEQ ID NO: 815), (SEQ ID NO: 819, SEQ ID NO: 820, SEQ ID NO: 821), (SEQ ID NO: 825, SEQ ID NO: 826, SEQ ID NO: 827), (SEQ ID NO: 831, SEQ ID NO: 832, SEQ ID NO: 833), (SEQ ID NO: 837, SEQ ID NO: 838, SEQ ID NO: 839), (SEQ ID NO: 843, SEQ ID NO: 844, SEQ ID NO: 845), (SEQ ID NO: 849, SEQ ID NO: 850, SEQ ID NO: 851), (SEQ ID NO: 855, SEQ ID NO: 856, SEQ ID NO: 857), (SEQ ID NO: 861, SEQ ID NO: 862, SEQ ID NO: 863), (SEQ ID NO: 867, SEQ ID NO: 868, SEQ ID NO: 869), (SEQ ID NO: 873, SEQ ID NO: 874, SEQ ID NO: 875), (SEQ ID NO: 879, SEQ ID NO: 880, SEQ ID NO: 881), and (SEQ ID NO: 885, SEQ ID NO: 886, SEQ ID NO: 887). A light chain variable region (VL) region comprising CDRs; (ii) (SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382), (SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO: 518), (SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 524), (SEQ ID NO: 528, SEQ ID NO: 529, SEQ ID NO: 530), (SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536), (SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542), (SEQ ID NO: 546, SEQ ID NO: 547, SEQ ID NO: 548), (SEQ ID NO: 552, SEQ ID NO: 553, SEQ ID NO: 554), (SEQ ID NO: 558, SEQ ID NO: 559, SEQ ID NO: 560), (SEQ ID NO: 564, SEQ ID NO: No. 565, No. 566), (SEQ ID NO: 570, SEQ ID NO: 571, SEQ ID NO: 572), (SEQ ID NO: 576, SEQ ID NO: 577, SEQ ID NO: 578), (SEQ ID NO: 582, SEQ ID NO: 583, SEQ ID NO: 584), (SEQ ID NO: 588, SEQ ID NO: 589, SEQ ID NO: 590), (SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 596), (SEQ ID NO: 600, SEQ ID NO: 601, SEQ ID NO: 602), (SEQ ID NO: 606, SEQ ID NO: 607, SEQ ID NO: 608), (SEQ ID NO: 612, SEQ ID NO: 613, SEQ ID NO: 614), (SEQ ID NO: 618, SEQ ID NO: 619, SEQ ID NO: 620), (SEQ ID NO: 621, SEQ ID NO: 622, SEQ ID NO: 623, SEQ ID NO: 624), (SEQ ID NO: 625, SEQ ID NO: 626, SEQ ID NO: 627, SEQ ID NO: 628), (SEQ ID NO: 629, SEQ ID NO: 630), (SEQ ID NO: 631, SEQ ID NO: 632), (SEQ ID NO: 633, SEQ ID NO: 634), (SEQ ID NO: 635, SEQ ID NO: 636), (SEQ ID NO: 637, SEQ ID NO: 638), (SEQ ID NO: 639, SEQ ID NO: 640), (SEQ ID NO: 641 Sequence number 624, sequence number 625, sequence number 626), (sequence number 630, sequence number 631, sequence number 632), (sequence number 636, sequence number 637, sequence number 638), (sequence number 642, sequence number 643, sequence number 644), (sequence number 648, sequence number 649, sequence number 650), (sequence number 654, sequence number 655, sequence number 656), (sequence number 660, sequence number 661, sequence number 662), (sequence number 666, sequence number 667, sequence number 668), (sequence number 672, sequence number 673, sequence number 674), (sequence number 678, sequence number 679, sequence Column number 680), (SEQ ID NO: 684, SEQ ID NO: 685, SEQ ID NO: 686), (SEQ ID NO: 690, SEQ ID NO: 691, SEQ ID NO: 692), (SEQ ID NO: 696, SEQ ID NO: 697, SEQ ID NO: 698), (SEQ ID NO: 702, SEQ ID NO: 703, SEQ ID NO: 704), (SEQ ID NO: 708, SEQ ID NO: 709, SEQ ID NO: 710), (SEQ ID NO: 714, SEQ ID NO: 715, SEQ ID NO: 716), (SEQ ID NO: 720, SEQ ID NO: 721, SEQ ID NO: 722), (SEQ ID NO: 726, SEQ ID NO: 727, SEQ ID NO: 728), (SEQ ID NO: 732, SEQ ID NO: 733, SEQ ID NO: 734), (SEQ ID NO: 738,SEQ ID NO:739, SEQ ID NO:740), (SEQ ID NO:744, SEQ ID NO:745, SEQ ID NO:746), (SEQ ID NO:750, SEQ ID NO:751, SEQ ID NO:752), (SEQ ID NO:756, SEQ ID NO:757, SEQ ID NO:758), (SEQ ID NO:762, SEQ ID NO:763, SEQ ID NO:764), (SEQ ID NO:768, SEQ ID NO:769, SEQ ID NO:770), (SEQ ID NO:774, SEQ ID NO:775, SEQ ID NO:776), (SEQ ID NO:780, SEQ ID NO:781, SEQ ID NO:782), (SEQ ID NO:786, SEQ ID NO:787, SEQ ID NO:788), (SEQ ID NO:792, SEQ ID NO:793, SEQ ID NO:794), (SEQ ID NO:798, SEQ ID NO:799, SEQ ID NO:800), (SEQ ID NO:804, SEQ ID NO:805, SEQ ID NO:806), (SEQ ID NO:810, SEQ ID NO:811, SEQ ID NO:812), (SEQ ID NO:816, SEQ ID NO:817, SEQ ID NO:818 and a heavy chain variable region (VH) region comprising a VH CDR selected from the VH (CDR1, CDR2, and CDR3) set consisting of: (SEQ ID NO:822, SEQ ID NO:823, SEQ ID NO:824), (SEQ ID NO:828, SEQ ID NO:829, SEQ ID NO:830), (SEQ ID NO:834, SEQ ID NO:835, SEQ ID NO:836), (SEQ ID NO:840, SEQ ID NO:841, SEQ ID NO:842), (SEQ ID NO:846, SEQ ID NO:847, SEQ ID NO:848), (SEQ ID NO:852, SEQ ID NO:853, SEQ ID NO:854), (SEQ ID NO:858, SEQ ID NO:859, SEQ ID NO:860), (SEQ ID NO:864, SEQ ID NO:865, SEQ ID NO:866), (SEQ ID NO:870, SEQ ID NO:871, SEQ ID NO:872), (SEQ ID NO:876, SEQ ID NO:877, SEQ ID NO:878), (SEQ ID NO:882, SEQ ID NO:883, SEQ ID NO:884), and (SEQ ID NO:888, SEQ ID NO:889, SEQ ID NO:890). ,
[0111] Properties of the CD47×CD20 bispecific entities of the invention In vitro affinity measurements using the extracellular domain of the effector antigen CD47 first revealed a 100-200 fold reduction in affinity for these variants. In vitro affinity measurements using the extracellular domain of CD47 revealed a 100-500 fold reduction in affinity for the variants. In vivo and in vitro cell-based studies using these deregulated IgG1 1+1 heterodimer format bispecifics confirmed effector-based cell killing and reduced binding to non-target cell types compared to monospecific antibodies. Anti-CD20 VL: SEQ ID NO: 323, Anti-CD20 VH: SEQ ID NO: 324. Anti-CD20 LC constant region is SEQ ID NO: 343. Anti-CD20 HC constant region is SEQ ID NO: 345.
[0112] The bispecific entities described, exemplified and claimed herein exhibit selective binding to CD20-expressing cells, for example by inhibiting the interaction of CD47 with the macrophage checkpoint inhibitor signal regulatory protein alpha (SIRPα). This increased selectivity over monospecific anti-CD47 approaches allows the use of IgG1 Fc, which engages the activation fragment crystallizable gamma receptor (FcγR), to fully potentiate macrophages to phagocytose and destroy CD20-positive cells. For example, compared to the anti-CD20 antibody rituximab, the anti-CD47 / anti-CD20 bispecific antibodies described and exemplified herein are more potent in inducing phagocytosis and ADCC in vitro.
[0113] In vitro cell-based studies demonstrate that the deconditioned CD47 bispecific entities described herein activate antibody-dependent cellular phagocytosis, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular cytotoxicity (ADCC). See Figures 4A-4C and 5A-5C. Furthermore, pharmacokinetic (PK) and exploratory toxicity (E-tox) study experiments in cynomolgus monkeys (cyno) demonstrated that the deconditioned CD47 bispecifics effectively depleted B cells and reduced binding to cynomolgus red blood cells (RBCs) compared to the parent monospecific anti-CD47 antibodies, thereby substantially confirming the success and medical value of the target cell selectivity strategy described and claimed herein. The species exemplified herein are CD20 mAbs with minimal adverse effects seen on hematological parameters after multiple administrations to non-human primates. + It exhibits favorable pharmacokinetics and depletion of B cells.
[0114] In certain embodiments, the CD47xCD20 bispecifics provided herein are designated TPP-1360, TPP-1361, TPP-1367, and TPP-1362 and comprise heavy and light chain sequences as follows: TPP-1360 comprises (CD47 LC SEQ ID NO:335, HC SEQ ID NO:336) x (CD20 LC SEQ ID NO:331, HC SEQ ID NO:332). TPP-1361 comprises (CD47 LC SEQ ID NO:333, HC SEQ ID NO:334) x (CD20 LC SEQ ID NO:331, HC SEQ ID NO:332). TPP-1367 comprises (CD47 LC SEQ ID NO:337, HC SEQ ID NO:338) x (CD20 LC SEQ ID NO:331, HC SEQ ID NO:332). TPP-1362 contains (CD47 LC SEQ ID NO: 385, HC SEQ ID NO: 386) x (CD20 LC SEQ ID NO: 331, HC SEQ ID NO: 332).
[0115] For TPP-1362, the CD47 VL comprises SEQ ID NO: 383. The CD47 VH of TPP-1362 comprises SEQ ID NO: 384. The CD47 VL CDRs of TPP-1362 comprise SEQ ID NO: 377 (CDRL1), SEQ ID NO: 378 (CDRL2), and SEQ ID NO: 379 (CDRL3). The CD47 VH CDRs of TPP-1362 comprise SEQ ID NO: 380 (CDRH1), SEQ ID NO: 381 (CDRH2), and SEQ ID NO: 382 (CDRH3).
[0116] A series of exemplary bispecific entities within the genus, described elsewhere herein, are demonstrated to generally exhibit pharmacological characteristics indicative of the therapeutic value of the genus. These highly evaluated species, for example, exhibit high affinity for CD20 and deregulated affinity for CD47, exhibit effective CD47 blocking, cyno-cross-reactivity, good physicochemical properties (solubility, stability, expression), and low predicted immunogenicity (EpiVax). See Example 15, Figure 18. The IgG1 heterodimer format and Fc confer reliable production in sufficient quantities and purity using standard CHO processes, with phase appropriate titers, yields, product quality and liquid composition. These highly evaluated exemplary species exhibit superior CD20 binding to CC-90002. + These highly evaluated exemplary species also show a marked reduction in cynomolgus B cells in peripheral blood and lymphoid tissues. These highly evaluated exemplary species also show a marked reduction in CD20 - CD47 + They exhibit minimal sink effects with no binding to healthy cells (RBCs and platelets). These highly valued exemplary species also exhibit acceptable PK parameters that support, for example, weekly dosing.
[0117] For example, the RBC binding ability of TPP-1360 was extensively evaluated in purified human RBCs and in co-cultures of human RBCs with tumor cells. As shown in FIG. 8, TPP-1360 binds to CD47 + / CD20 +selectively binds to Raji cells, but not to CD47 + / CD20 - Furthermore, in co-cultures of Raji cells with human RBCs, TPP-1360 binds to CD47 + / CD20 + It showed dose-dependent binding to Raji cells, but no binding to human RBCs even at a high concentration of 1 mg / mL. See Figure 9. Instead, CD47 wild type / CD20 bispecific TPP-2 bound significantly to both Raji cells and human RBCs. Furthermore, TPP-1360 shows no binding to purified cynomolgus monkey RBCs from multiple donors.
[0118] TPP-1360, an exemplary type of bispecific entity of the present disclosure, is a first-in-class antibody that co-targets CD47 and CD20 and is designed to bind CD20 with high affinity and CD47 with optimally detuned affinity. When bound to CD20-expressing cells, for example, TPP-1360 not only blocks the interaction of the macrophage checkpoint inhibitor SIRPα with CD47, but also engages in FcγR activation, fully recruiting macrophages to phagocytose and destroy CD20-positive cells. Potential in vitro activity is induced by TPP-1360 to eliminate cancer cells through multiple modes of action including, for example, phagocytosis, ADCC, and CDC. TPP-1360, an exemplary bispecific entity described herein, provides enhanced pharmacological activity over rituximab and CC-90002.
[0119] The CD47×CD20 bispecific entities described and claimed herein exhibit enhanced phagocytosis compared to rituximab or CC-90002 as single agents. The phagocytic activity of the CD47×CD20 bispecific entities described herein generally correlates with their CD47 binding affinity. The CD47×CD20 bispecific entities described herein have comparable single agent activity to the combination of CC-90002 and rituximab in inducing phagocytosis.
[0120] The CD47xCD20 bispecific entities described herein exhibit improved ADCC in rituximab-sensitive and -resistant tumor cells compared to single agent anti-CD47 activity.
[0121] The CD47xCD20 bispecific entity described herein shows superior efficacy to rituximab in vivo in the Raji NOD-SCID model. See Example 16.
[0122] TPP-1360 enhances both phagocytosis and ADCC activity over Rituximab. In addition, TPP-1360 and related bispecific entities described, exemplified, and claimed herein are differentiated from CD20×CD3 bispecific T cell engagers such as REGN1979 from Regeneron or mosunetuzumab from Roche (currently in clinical use) because they have different modes of action including phagocytosis, ADCC, and CDC compared to T cell activation. In addition, the toxicity profile is also different from CD20×CD3 (potential hematologic toxicity vs. cytokine release syndrome). In particular, T cell engagers are potent immune engagers and may cause apoptosis of non-target cells expressing very low levels of the target antigen, therefore the target antigen must be highly specific or the anti-target arm of the bispecific must be tailored to use masking techniques or to distinguish between the expression levels of the target antigen on normal and diseased tissues. In addition, the anti-CD3 portion of the bispecific must be precisely tailored to prevent cytokine release due to systemic activation of T cells. Importantly, TPP-1360, as exemplified herein, exhibits favorable clearance kinetics with minimal adverse effects on hematological parameters following multiple administrations to non-human primates. The CD47xCD20 bispecific antibody of the present invention is developed as an intravenous (IV) injection treatment, inter alia, for B lymphoma patients, e.g., those refractory and / or resistant to current therapies.
[0123] The bispecific entities described herein provide methods of treatment and / or inhibition of tumors, tumor cells, cancers, including, but not limited to, abnormally proliferating cells, hematological oncological conditions, hematological malignancies, lymphoproliferative disorders, B cell disorders, B cell malignancies, and / or B cell lymphomas. The bispecific entities of the invention are formulated and administered as therapeutic entities according to the state of the art for antibodies. For example, standards of formulation and administration of IgG1 antibodies are well known in the art. The antibodies described herein are administered, for example, as intravenous (IV) injection treatments for patients with CD20 positive B cell lymphomas. The present invention is directed to a method of inhibiting tumor cells, comprising administering to a patient in need thereof an effective amount of the bispecific entities described herein. Tumor cells refer to cancer cells, including, but not limited to, abnormally proliferating cells, hematological oncological conditions, hematological malignancies, lymphoproliferative disorders, B cell disorders, B cell malignancies, and B cell lymphomas.
[0124] The CD47xCD20 bispecific entities described herein are particularly provided for use in a method of treatment of a B cell disorder or B cell malignancy comprising administering to a patient in need thereof an effective amount of a bispecific entity described herein.
[0125] Allometry and human pharmacokinetics are evaluated for the bispecific entities described herein. The entities of the present invention comprise a deregulated CD47 binding arm and a regular CD20 (rituximab) binding arm. Given the deregulated binding affinity of the CD47 arm, target-mediated drug elimination (TMDD) for the bispecific entities is potentially driven primarily by CD20 binding. Thus, in certain embodiments, the clinical dose is within the range of doses currently used for rituximab. Based on doses of 10, 20, and 100 mg / kg in cynomolgus monkeys, the terminal half-life is approximately 7 days. CD20-mediated TMDD is based on additional preclinical and clinical data for rituximab. The first-in-human clinical trial is an open-label, multicenter, Phase 1 / 1b study to evaluate the safety and tolerability of subjects with relapsed or refractory CD20+ NHL that has progressed on rituximab and / or other CD20-targeted therapies. Dose escalation begins at less than 1 mg / kg and then titrates to 10 mg / kg, the current clinical dose of rituximab. Cynomolgus monkeys were dosed at 20 mg / kg twice, on days 1 and 15. The bispecific entities described herein have been found to be well tolerated as single agents in the NHP eTOX study with dose-proportional exposure. Mammalian or human doses of the bispecific entities described herein are in the range of about 3 mg / kg to about 20 mg / kg. Further mammalian or human doses of the bispecific entities described herein are particularly in the range of about 5 mg / kg to about 15 mg / kg. Also, mammalian or human doses of the bispecific entities described herein are about 7 mg / kg to about 13 mg / kg. Dosing regimens of the bispecific entities described herein are about once every 5 days, or about once per week (7 days), or about once per 10 days, or about once every 2 weeks.
[0126] The manufacturing process of bispecific antibodies described herein may follow a typical Chinese Hamster Ovary (CHO) manufacturing platform. A common contaminant observed in the purification of bispecific antibodies is half antibodies, which require specific purification protocols to remove. After expression of the four-chain bispecific in Chinese Hamster Ovary cells, Protein A is used as the first step to purify the IgG-based bispecific. Following this first step, generally there are two species: the desired four-chain bispecific antibody and half antibodies. In most cases, ion exchange chromatography is sufficient to separate these two species, but in other cases, hydrophobic interaction chromatography may be required. The correct pairing of LCs should be assessed by mass spectrometry and misassembly impurities should be removed by additional protein purification methods such as ion exchange or hydrophobic interaction chromatography. Following any of the secondary purification approaches, preparative size exclusion chromatography (SEC) can be used to polish and ensure conformational uniformity while buffer exchanging the four-chain bispecific. Final quality control should include analytical SEC, mass spectrometry, and in vitro binding evaluation with different antigens to ensure the conformational and chemical integrity of the bispecific. See, for example, J.B Ridgway et al., Protein Eng. 9 (1996) 617-621; K. Gunasekaran et al., J.Biol.Chem.285 (2010) 19637-19646. Preferred monomer elements of the IgG1 1+1 heterodimers described herein each comprise specific LC and HC constant region sequences discussed above and are identified herein to reduce the propensity for homodimer formation during production of the IgG1 1+1 heterodimer format.
[0127] Parental anti-CD47 antibody CL-4033 from deregulated OMT-derived species Also provided is an anti-CD47 antibody comprising a VL region comprising VL CDR1 RASQGISSWLA (SEQ ID NO: 893), VL CDR2 AASVLES (SEQ ID NO: 894), VL CDR3 QQANSFPYT (SEQ ID NO: 895), and a variable heavy chain (VH) comprising VH CDR1 NFVMS (SEQ ID NO: 896), VH CDR2 TISGSGGGSTYYADSVKG (SEQ ID NO: 897), and VH CDR3 HHILRYFD (SEQ ID NO: 898). Also provided is an anti-CD47 antibody comprising a VL region comprising SEQ ID NO: 891, and a VH region comprising SEQ ID NO: 892. Anti-CD47 antibody CL-4033 is the parent antibody of the deregulated OMT-derived anti-CD47 VL / VH Fab described herein. See Example 2.
[0128] An antibody comprising a VL region comprising SEQ ID NO:891, and a VH region comprising SEQ ID NO:892, and / or VL CDR1 (SEQ ID NO:893), VL CDR2 (SEQ ID NO:894), VL CDR3 (SEQ ID NO:895), and VH CDR1 (SEQ ID NO:896), VH CDR2 (SEQ ID NO:897), and VH CDR3 (SEQ ID NO:898) can be an immunoglobulin molecule of any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgGA1 or IgGA2), or any subclass (e.g., IgG2a or IgG2b).
[0129] Additionally, the present invention is directed to a pharmaceutical composition for the inhibition of tumor cells, comprising an anti-CD47 antibody described herein, for administration to a patient in need thereof.
[0130] Additionally, the present invention is directed to a pharmaceutical composition for the treatment of a B cell disorder or B cell malignancy, comprising an anti-CD47 antibody described herein, for administration to a patient in need thereof.
[0131] The present invention is further directed to a method of inhibiting tumor cells, comprising administering to a patient in need thereof an effective amount of an antibody described herein.
[0132] The present invention is further directed to a method of treating a B cell disorder or B cell malignancy, comprising administering to a patient in need thereof an effective amount of an antibody described herein. EXAMPLES
[0133] Example 1: Deconditioning of CC-90002 Rational design to reduce the affinity of the anti-CD47 arm of the non-detuned parent version CC-90002 (408_437) was made possible by the crystal structure of the anti-CD47 Fab bound to the extracellular domain of CD47. The epitope bound by CC-90002 is identical to that of the original murine anti-CD47 2A1 bound to human CD47. See U.S. Patent No. 9,045,541.
[0134] The variable domain of 2A1 was humanized, and the final antibody consisting of HC_2.3Q and LC_N was named "QN" and finally developed as an IgG4P / E format (CC-90002). QN was further modified by introducing residues in the variable heavy domain to improve cell-free expression. This HC variant was named "HC_Q_5_MUT". HC_Q_5_MUT HC and LC_N were further modified to reduce their immunogenicity using in silico modeling and in silico prediction of immunogenicity. These are collectively referred to as "CD47 2.0". Further variants in the variable heavy and variable light domains of CD47 2.0 LC_1147_2 and CD47 2.0 HC_434 were designed to improve pharmacokinetics. These are referred to as "CD473.0". See WO2016 / 109415 (US2017 / 0369572), WO2018 / 009499 (US2019 / 0241654), and WO2018 / 183182, each of which is incorporated by reference herein.
[0135] The anti-CD47 epitope covers a large surface area and residues from both the light chain (LC) and the heavy chain (HC) are involved in the interaction.
[0136] To reduce the affinity of the anti-CD47 arm for CD47, CD47-interacting residues from both the LC and HC were subjected to in silico mutagenesis using the "residue scan" module from the Molecular Operating Environment (MOE) modeling program. This process created a library of thousands of variants with a wide range of predicted affinities. Each of the in silico Fab variants was modeled to calculate the predicted change in stability (dStability) or change in affinity for CD47 ECD (dAffinity). Over 5,000 variants with positive dAffinity scores (predicted to have lower affinity compared to the parent Fab) and negative dStability (predicted to have higher stability than the parent Fab) were analyzed using immunogenicity assessment software to identify variants predicted to have low immunogenicity. Of these, 143 Fab variants with low risk of immunogenicity, with predicted Kd for CD47 in the range of 10 nM to 1 mM, were selected for cell-based testing.
[0137] To screen for target cell selective anti-CD47 Fabs, selected anti-CD47 Fab variants were constructed as IgG1 fusions and paired with anti-EGFR arms derived from cetuximab. Proper assembly of the 4-chain bispecific was enabled by the presence of the Fab and Fc substitutions described herein in all 4 chains. The 4-chain bispecifics containing the 143 selected variants were transiently expressed in Expi-CHO cells and the bispecifics were purified in a single step using magnetic protein A beads. To identify target cell selective bispecifics, the variants were tested in two experiments. The first experiment measured the ability of the deregulated anti-CD47 x anti-EGFR bispecifics to bind to the non-target Raji cell line, which expresses the CD47 antigen but not the EGFR antigen. The second experiment measured the ability of the deregulated anti-CD47 x anti-EGFR bispecifics to block SIRPα binding to the target Fadu cell line, which expresses the CD47 and EGFR antigens. These experiments yielded a set of eight variants that had a 10- to 20-fold reduced affinity for the non-targeted CD47+ / EGFR-Raji cell line compared to the non-deconditioned anti-CD47 × anti-EGFR parent antibody, but were still able to block SIRPα binding to the CD47+ / EGFR+Fadu target cell line by 75-90%.
[0138] Similarly, the anti-CD20 arm of rituximab was paired with eight deregulated anti-CD47 variants using IgG1 Fc. It was observed that the deregulated CD47xCD20 bispecific had reduced binding to the CD47+ / CD20- non-targeted Fadu cell line compared to the non-deregulated CD47xCD20 parent antibody, but was still able to block SIRPα binding to the target Raji cell line, which is CD47 and CD20 positive, by 75-90%.
[0139] Evaluation of the variants for further development potential led to the selection of a single anti-CD47 Fab variant VH E59Y / S102E cloned into three CC-90002-derived frameworks for pharmacokinetic studies in cynomolgus monkeys: TPP-1367, TPP-1360, and TPP-1361.
[0140] Example 2: Description of OMT-derived deregulation and screening to identify favorable variants OmniRat animals were immunized with the extracellular domain (ECD) of human CD47. OmniRat animals are transgenic animals that express a repertoire of human light and heavy chains such that antibodies produced in response to immunization contain entirely human sequences. From this immunization campaign, one antibody (designated M2) was discovered that appeared to meet the required functional attributes. To further develop M2, 37 variants in the light chain CDRL2 of M2 were generated in an attempt to reduce its potential immunogenicity. These were expressed in a 24-well format and the supernatants were screened for binding to human CD47 using a Biacore 8K instrument. From these 37 variants, 11 were selected for further development based on conservation of function, expressibility, and predicted low immunogenicity. From these 11 variants, one antibody (designated CL-4033) was selected for deregulation.
[0141] A homology model of CL-4033 was constructed, and a library of variants was designed that predicted to have a range of low affinity with good stability and low immunogenicity. 64 deregulated CL-4033 variants were then paired with the anti-CD20 arm of rituximab, consisting of substitutions designed to reduce homodimer formation as described herein, transiently expressed in ExpiCHO, purified, and analyzed for binding to Fadu cells that express CD47 but not CD20. Ten variants that showed low binding to Fadu cells were then tested for their ability to block human SIRPα binding to Raji cells. One variant, CL-4033-H100Y, demonstrated the greatest amount of human SIRPα blocking to Raji target cells and had weak affinity to non-target FADU cells. This variant was named TPP-1362.
[0142] Example 3: Summary of SPR binding results for rituximab binding to CD20 Since the CD20 antigen cannot be purified for in vitro binding experiments (i.e., SPR), anti-CD20 affinity measurements are performed on cells. An exemplary effective concentration (EC 50 ) was found to be about 1.1 nM according to FIG.
[0143] Example 4: Summary of SPR binding results for bispecific entities described herein Surface plasmon resonance (SPR) experiments were used to measure the affinity of TPP-1360 and TPP-1362 to CD47. These two antibodies were tested for binding to human CD47 and cynomolgus CD47 and were found not to bind to mouse CD47. TPP-1360 was measured to have an affinity to human CD47 ECD with a Kd of 1.7 μM, reflecting an affinity reduction of about 350-fold compared to the parent anti-CD47 binder. The affinity of TPP-1360 to cynomolgus CD47 ECD was found to have a Kd of 4.51 μM. TPP-1362 was measured to have an affinity to human CD47 ECD with a Kd of 0.796 μM, reflecting an affinity reduction of about 150-fold compared to the parent anti-CD47 binder. The affinity of TPP-1362 for cynomolgus monkey CD47 ECD was found to have a Kd of 2.06 μM. Finally, in addition to the measured affinity, a sandwich SPR assay demonstrated simultaneous binding to both CD47 and CD20.
[0144] Example 5: Binding of Exemplary Bispecific Entities and Dose Response of SIRPα Blockade Dose-response curves were generated for TPP-1360 and TPP-1362 blockade of human SIRPα binding to various CD20-expressing non-Hodgkin's lymphoma tumor cell lines. The cell lines were incubated with increasing concentrations of either bispecific, and then human SIRPα was added at saturating concentrations. In addition to the bispecifics, rituximab and a parental anti-CD47 binder (TPP-23, CD47 2.0 408_437 with IgG1) were included for reference. The cells were washed and then incubated with a secondary antibody to measure the amount of SIRPα bound to the tumor cells. For the cell line OCI-Ly3 (DLBCL cell line), TPP-1360 was found to have an EC50=1.30 nM, and TPP-1362 was found to have an EC50=0.70 nM. For the Raji cell line (B-lymphocyte Burkitt's lymphoma cell line), TPP-1360 was found to have an EC50=1.64 nM and TPP-1362 was found to have an EC50=1.10 nM. As shown in Figure 21, the parental anti-CD47, TPP-23, had an EC50 of 0.11 nM to block human SIRPα binding to OCI-Ly3 cells. 50 Rituximab had no effect on SIRPα binding.
[0145] Example 6: Dose response for phagocytosis Dose-response curves for TPP-1360 and TPP-1362 activation of phagocytosis against various CD20-expressing non-Hodgkin's lymphoma tumor cell lines were generated. Human monocytes were differentiated into macrophages and then added to tumor cell lines and incubated with increasing concentrations of either bispecific. In addition to the bispecific entities, rituximab and a parental anti-CD47 binder (TPP-23) were included for reference. Fluorescent labeling of macrophages and tumor cells was used to measure the number of phagocytic events using an image-based quantification method. For the OCI-Ly3 cell line, TPP-1360 was found to have an EC50=1.4nM and TPP-1362 was found to have an EC50=0.43nM. For the Raji cell line, TPP-1360 was found to have an EC50=1.8 nM and TPP-1362 was found to have an EC50=0.37 nM.
[0146] Example 7: Binding studies with human and cynomolgus monkey RBCs and hemagglutination The binding of certain exemplary bispecific entities to human and cynomolgus RBCs was determined and their potential to bind non-target cells was evaluated. RBCs were isolated from whole blood and incubated with increasing concentrations of exemplary bispecifics. Binding was expressed as a percentage of the amount of binding observed with the parent anti-CD47 binder (TPP-23) at 2 μg / ml. At 200 μg / ml, TPP-1360 and TPP-1361 bound to human RBCs with less than 1% of the binding seen for the parent anti-CD47 binding. Similarly, at 200 μg / ml, TPP-1360 bound to cynomolgus RBCs with less than 1% of the binding seen for the parent anti-CD47 binding. A higher degree of binding was observed for TPP-1362 binding to cynomolgus RBCs at 200 μg / ml, showing 2-3% of the binding of the parent anti-CD47 binder. Finally, both lead parent anti-CD47 binders showed no hemagglutination of human RBCs at 200 μg / ml. Similarly, both TPP-1360 and TPP-1361 showed no hemagglutination at 200 μg / ml. BRIC6, a known hemagglutinating antibody, was used as a positive control.
[0147] Example 8: Binding studies to human PBMC and whole blood The binding of the bispecific entities described herein to human peripheral blood mononuclear cells (PBMCs) was evaluated. Compared to the parent anti-CD47 binders TPP-23 and rituximab, the TPP-1360 bispecific showed less binding to all cell types, with the exception of B cells, which showed significant binding due to the presence of the anti-CD20 Fab portion.
[0148] Example 9: Cynomolgus monkey PK in the lead of the first round Cynomolgus monkey PK studies were performed using the bispecific species examples described herein. Cynomolgus monkeys were dosed with 20 mg / kg twice on days 1 and 15. B cell depletion was observed. From these studies, TPP-1360 and TPP-1362 were selected for further study in cynomolgus monkey exploratory toxicity (E-tox) studies, as described in Example 10.
[0149] Example 10: Round 2 Lead Cynomolgus E-tox Cynomolgus E-tox studies were conducted with TPP-1360 and TPP-1362. For TPP-1360, cynomolgus monkeys were dosed at 100, 20, and 10 mg / kg once a week for 2 weeks, followed by a 2-week off-period. The second TPP-1360 arm was tested at 10 mg / kg twice a week for 2 weeks, followed by a 2-week off-period. For TPP-1362, cynomolgus monkeys were dosed at 60, 20, and 10 mg / kg once a week for 2 weeks, followed by a 2-week off-period. The second TPP-1362 arm was tested at 10 mg / kg twice a week for 2 weeks, followed by a 2-week off-period, and 20 mg / kg twice on days 1 and 15. These studies demonstrated that TPP-1360 was well tolerated, exhibited profound B cell depletion, and achieved dose-proportional exposure, thus avoiding sinks and confirming that it is target cell selective.
[0150] Example 11: In vitro pharmacology A. Human whole blood binding To evaluate the specificity of TPP-1360, its binding profile was first evaluated in whole blood using flow cytometry. Across two donors, 200nM TPP-1360 shifted the binding signal toward B cells, but rather weakly shifted it substantially toward T cells, monocytes, and NK cells, with minimal or no binding to platelets or erythrocytes. This indicated selective binding to B cells in human whole blood. See Figure 7.
[0151] Figure 7 shows that bispecific TPP-1360, for example, binds primarily to B cells with very little binding to the other cell types listed (possibly due to higher levels of CD47 than those found on blood cells or due to Fc contributions that may engage Fc receptors expressed on NK cells and monocytes). Conversely, TPP-23, a high affinity CD47 monospecific antibody, binds to all of these cell types due to the ubiquitous expression of CD47 and the high affinity for CD47 found in TPP-23.
[0152] The overall binding profile of TPP-1360 in human whole blood is similar to that of rituximab. Conversely, the parent CD47 mAb, TPP-23, used as a control for CD47 expression, bound significantly to all cell populations in human blood.
[0153] B. Tumor cell binding Furthermore, for example, the RBC binding ability of TPP-1360 was extensively evaluated in purified human RBCs and in co-cultures of human RBCs with tumor cells. As shown in FIG. 8, TPP-1360 binds CD47 + / CD20 + Selectively bound to Raji cells, but not to CD47 + / CD20 - Furthermore, in co-cultures of Raji cells with human RBCs, TPP-1360 inhibited the binding of CD47 + / CD20 +It showed dose-dependent binding to Raji cells, but no binding to human RBCs, even at a high concentration of 1 mg / mL. See Figure 9. Instead, the parent CD47 / CD20 bispecific, TPP-2, bound significantly to both Raji cells and human RBCs. Furthermore, TPP-1360 shows no binding to purified cynomolgus monkey RBCs from multiple donors.
[0154] C. SIRPα competition CD20 + / CD47 + After demonstrating selective binding to cells, we assessed the ability of TPP-1360 to antagonize the interaction of human SIRPα with cell surface CD47 using an in vitro competition assay. TPP-1360 binds to CD20 + / CD47 + TPP-1360 potently blocked the binding of recombinant human SIRPα-Fc to human CD47 expressed on the surface of lymphoma cell lines OCI-Ly3 and Raji with average EC50 values of 1.30 nM and 1.64 nM, respectively. See Figures 10 and 11. Figure 10 shows that TPP-1360 inhibits, e.g., CD20 + / CD47 + Figure 11 shows that TPP-1360 potently and completely blocked the binding of recombinant human SIRPα-Fc to human CD47 expressed on the surface of the lymphoma cell line OCI-Ly3. + / CD47 + We show that TPP-1360 potently and completely blocks recombinant human SIRPα-Fc binding to human CD47 expressed on the surface of the lymphoma cell line Raji. In contrast, neither rituximab nor control bispecific antibody TPP-1480 (anti-CD20 / hen egg lysozyme) can compete with human SIRPα-Fc binding to the same cell line. The data presented herein also demonstrate that TPP-1360 is less potent than TPP-23 in blocking human SIRPα-CD47 interaction, consistent with the attenuated affinity of TPP-1360 to human CD47.
[0155] Example 12: Functional Activity: Human Macrophage Phagocytosis This example demonstrates the ability of TPP-1360 to induce tumor phagocytosis and “eaten” CD20 in labeled macrophages. + CD47 + It is determined in vitro by automated counting of tumor cells.
[0156] Expression of CD20 and CD47 was first verified in each of the target tumor cell lines (OCI-Ly3, Raji, REC-1, and RIVA) by quantifying antibody binding capacity (ABC) using a flow cytometry assay (Denny TN et al., Cytometry. 1996 Dec;26(4):265-74). All four cell lines express high levels of CD47 and CD20. Table 1: Antigen expression of CD47 and CD20 on lymphoma cell surface. [Table 1] ABC=antibody binding capacity.
[0157] The titrated antibodies were then added to pre-differentiated macrophages, followed by co-culture with carboxyfluorescein succinimidyl ester (CSFE)-labeled tumor cells opsonized with TPP-1360. Phagocytic activity was quantitatively determined by the number of labeled tumor cells within the labeled macrophages. Green intensity (CFSE) was measured in each of the CD14 allophycocyanin (APC)-labeled macrophages, and a threshold gate was used to identify CFSE-positive macrophages. Across experiments, a threshold of approximately 1000 MFI (mean fluorescence intensity) with a variance of less than several hundred MFIs was observed. For each sample, the calculated percentage of phagocytosis was determined as [(number of CFSE-positive macrophages) / (total number of macrophages)] × 100. Across at least two donors, treatment with TPP-1360 significantly increased the number of CD20 cells in the four CD20 +Macrophage-mediated phagocytosis of malignant B-cell lines was induced. Representative data from one donor are shown in Figure 12 (Raji cells), Figure 13 (OCI-Ly3 cells), Figure 14 (REC-1 cells), and Figure 15 (RIVA cells). Area under the curve was calculated followed by paired t-test to determine the statistical significance of TPP-1360 compared to Rituximab. See Figure 16. The data demonstrate that treatment with TPP-1360 caused significantly more efficient phagocytosis than Rituximab in Raji and OCI-Ly3 cells, likely due to the simultaneous blockade of SIRPα-CD47 interaction by TPP-1360 and the engagement of activating receptors such as FcγR.
[0158] Example 13: Pharmacokinetics Non-GLP studies were conducted in mice and cynomolgus monkeys to determine the pharmacokinetic (PK) profiles of the bispecific entities (antibody species described herein, TPP-1360, TPP-1361, TPP-1362, and TPP-1367). Single-dose mouse PK studies were conducted using naïve female NOD / SCID mice, where 10 mg / kg of antibody was administered via intraperitoneal (IP) injection. Sparse PK sampling (n=4 / time point) was performed over 72 hours, and all animals showed detectable antibody species concentrations throughout the study period. The calculated half-life was 3.4 days, but may be an underestimate given the sampling period. To evaluate the PK profile in cynomolgus monkeys, a repeat-dose exploratory toxicity study was conducted, where 20 mg / kg of antibody species was administered via IV bolus injection on days 1 and 15 to three naïve male monkeys. Following repeated dosing of the antibody species, systemic exposure was achieved and the antibody species was detectable in the serum of two of the three monkeys throughout the entire study period (336 hours after dosing on day 15). Samples were also collected as part of the repeat-dose study for hematological and immunophenotypic evaluation. The observed depletion of B lymphocytes demonstrates drug function in vivo. Overall, antibody species exposure was maintained throughout the entire study period in both the single-dose mouse and repeat-dose monkey studies, with similar half-lives reported between the two studies, ranging from 3 to 3.5 days.
[0159] Example 14: Safety Profile This series of highly valued species examples showed acceptable toxicity profiles (e.g., well tolerated up to 100 mg / kg QW, the highest dose tested). Toxicokinetics was evaluated as part of a 28-day exploratory toxicity study in cynomolgus monkeys. TPP-1360 was administered via IV injection to cynomolgus monkeys (4 / group) at a dose level of 10 mg / kg (BIW) on days 1, 4, 8, 11, and 15, or at 20 mg / kg and 100 mg / kg (QW) on days 1, 8, and 15, either BIW or QW. Anti-rituximab antibody for capture and goat anti-human IgG for detection were used. Serum concentrations were measured by sandwich ELISA using Fc. Following multiple IV doses of 10, 20, or 100 mg / kg, systemic exposure to TPP-1360 was achieved at all dose levels and maintained in all animals throughout the study period. TPP-1360 significantly increased C max and AUC 0-168 The drug showed a linear TK with an approximately dose-proportional increase at 10 mg / kg. After the first dose, clearance was similar over the dose range of 10 to 100 mg / kg, suggesting target saturation at the 10 mg / kg dose. AUCValues indicate some accumulation of TPP-1360 by the fifth and third doses in the 10 mg / kg (BIW) and 100 mg / kg (QW) dose groups. Mean calculated half-lives ranged from 2 to 4 days, depending on dose level and dose regimen. Anti-drug antibodies were detected in 5 of 8 animals tested on day 15 prior to dosing, and in 5 of 6 animals tested on study day 29. Anti-drug antibodies affected TPP-1360 exposure, as evidenced by the observed reduction in exposure in ADA-positive animals. TPP-1360 was well tolerated up to 100 mg / kg QW, the highest dose tested. Reductions in B cells in peripheral blood and multiple lymphoid tissues were seen at 10 mg / kg BIW, and at 20 mg / kg QW and above, indicating robust pharmacodynamic activity. Dosing at 10 mg / kg BIW provided no additional benefit over 20 mg / kg QW. In addition to effects on B cells, TPP-1360 also depleted T and NK cells at all dose levels, neutrophils at ≥ 20 mg / kg QW, and red blood cells at 100 mg / kg QW. However, no test sample-related platelet depletion was observed. The depletion of T cells, NK cells, neutrophils, and red blood cells is likely mediated by the CD47 arm of TPP-1360, as these cells do not express CD20.
[0160] Example 15: Immunogenicity The Interactive Screening and Protein Reengineering Interface (ISPRI) software developed by EpiVax is an in silico computational method used to evaluate potential antibody immunogenicity in humans and is known to be a clinically well-established T cell-dependent analysis tool (Figure 18). The amino acid sequences of the VH and VL of TPP-1360 were analyzed for putative T effector and T regulatory hotspots and were found to have a low risk of immunogenicity.
[0161] Example 16: Raji xenograft model The CD47xCD20 bispecific entity described herein demonstrates superior efficacy to rituximab in vivo in the Raji NOD-SCID model. The objective of this study was to determine the single-agent antitumor activity of TPP-1360 or TPP-1362 in the Raji xenograft model, which expresses lower levels of CD20 and higher levels of CD47. Female NOD-SCID mice were inoculated with Raji cells in the right flank. Dosing was performed at 10-20 days after tumor growth, when tumor size was approximately 270 mm. 3 Treatment was started when the tumor volume was 100 mg / kg. TPP-1360 and TPP-1362 were tested at 10 mg / kg and 30 mg / kg, administered once weekly (QW) for 2 weeks. Rituximab, which is bivalent for CD20, was used as a control drug with the same administration paradigm. Final tumor volume reduction was measured at the end of the study on day 25, when the mean tumor volume in the isotype control (anti-RSV IgG1) group was approximately 2000 mm 3 It was determined when the tumor volume reached 10 mg / kg QW. Significant (p<0.0001) antitumor activity of TPP-1360, with a 52% reduction in tumor volume, was observed at both 10 and 30 mg / kg QW. Significant antitumor activity of TPP-1362 was also observed, with a 62% tumor reduction at 10 mg / kg QW or a 64% tumor reduction at 30 mg / kg QW (Figures 19-20). In the same dosing regimen, rituximab showed a 33% and 38% reduction in tumor volume at 30 mg / kg and 10 mg / kg, respectively. The antitumor activity of TPP-1360 at 30 mg / kg QW was significantly better (p<0.01) than that of rituximab at the corresponding dose level, suggesting the contribution of the CD47 arm in the antitumor activity of TPP-1360. The antitumor activity of TPP-1362 at 30 mg / kg QW was also significantly better than rituximab at the corresponding dose level (p<0.0001), suggesting a contribution of the CD47 arm in the antitumor activity of TPP-1362. There was no significant weight loss in animals treated with isotype control, TPP-1360, TPP-1362, or rituximab. Table 2. Sequence Listing [Table 2-1]
Table 2-2
Table 2-3
Table 2-4
Table 2-5
Table 2-6
Table 2-7
Table 2-8
Table 2-9
Table 2-10
Table 2-11
Table 2-12
Table 2-13
Table 2-14
Table 2-15
Table 2-16
Table 2-17
Table 2-18
Table 2-19
Table 2-20
Table 2-21
Table 2-22
Table 2-23
Table 2-24
Table 2-25
Table 2-26
Table 2-27
Table 2-28
Table 2-29
Table 2-30
Table 2-31
Table 2-32
Table 2-33
Table 2-34
Table 2-35
Table 2-36
Table 2-37
Table 2-38
Table 2-39
Table 2-40
Table 2-41
Table 2-42
Table 2-43
Table 2-44
Table 2-45
Table 2-46
Table 2-47
Table 2-48
Table 2-49
Table 2-50
Table 2-51
[0162] All publications and patents referenced herein are incorporated by reference.Various modifications and variations of the described subject matter will be apparent to those skilled in the art without departing from the scope and spirit of the invention.Although the present invention has been described in connection with specific embodiments, it should be understood that the claimed invention should not be unduly limited to these embodiments.Indeed, various modifications for implementing the present invention will be apparent to those skilled in the art and are intended to be within the scope of the following claims.
Claims
1. 1. A bispecific antibody comprising at least one Fab portion that binds CD47 and at least one Fab portion that binds CD20, wherein the Fab portion that binds CD47 comprises (i) a light chain variable region (VL) comprising VL CDRs RASQGISSWLA (SEQ ID NO: 377), AASVLES (SEQ ID NO: 378), and QQANSFPYT (SEQ ID NO: 379), and (ii) a heavy chain variable region (VH) comprising VH CDRs NFVMS (SEQ ID NO: 380), TISGSGGSTYYADSVKG (SEQ ID NO: 381), and HYILRYFD (SEQ ID NO: 382), and exhibits an affinity for CD47 of 0.5 μM to 25 μM; and the Fab portion that binds CD20 exhibits an affinity for CD20 of 0.4 nM to 12 nM; and the bispecific antibody selectively binds to CD47 on tumor cells and inhibits CD20- / A bispecific antibody that binds to less than 5% of CD47 on CD47 + cells.
2. The bispecific antibody of claim 1 , which selectively binds to B cells.
3. The bispecific antibody of claim 2 which is of isotype IgG1.
4. The bispecific antibody of claim 3, wherein the Fab portion that binds CD47 comprises a light chain (LC) region comprising SEQ ID NO:
340.
5. The bispecific antibody of claim 4, comprising an anti-CD47 heavy chain (HC) constant region comprising sequence number 342.
6. The bispecific antibody of claim 3, which selectively binds to malignant B cells.
7. The bispecific antibody of claim 5, which selectively binds to malignant B cells.
8. The bispecific antibody of claim 7, wherein the Fab portion that binds CD20 comprises a light chain (LC) region comprising SEQ ID NO:
344.
9. The bispecific antibody of claim 8, comprising an anti-CD20 heavy chain (HC) constant region comprising sequence number 346.
10. 2. The bispecific antibody of claim 1 , comprising a VL region comprising SEQ ID NO: 383 and a VH region comprising SEQ ID NO:
384.
11. 10. The bispecific antibody of claim 9, comprising the anti-CD20 VL CDRs RASSSVSYIH (SEQ ID NO: 353), ATSNLAS (SEQ ID NO: 354), QQWTSNPPT (SEQ ID NO: 355) and the VH CDRs SYNMH (SEQ ID NO: 356), AIYPGNGDTSYNQKFKG (SEQ ID NO: 357), STYYGGDWYFNV (SEQ ID NO: 358).
12. 12. The bispecific antibody of claim 11 , comprising an anti-CD20 VL region comprising SEQ ID NO: 323 and a VH region comprising SEQ ID NO:
324.
13. 13. The bispecific antibody of claim 12, comprising an anti-CD20 LC region comprising SEQ ID NO: 331 and an anti-CD20 HC region comprising SEQ ID NO:
332.
14. 11. The bispecific antibody of claim 10, comprising the anti-CD20 VL CDRs RASSSVSYIH (SEQ ID NO: 353), ATSNLAS (SEQ ID NO: 354), QQWTSNPPT (SEQ ID NO: 355) and the VH CDRs SYNMH (SEQ ID NO: 356), AIYPGNGDTSYNQKFKG (SEQ ID NO: 357), STYYGGDWYFNV (SEQ ID NO: 358).
15. 15. The bispecific antibody of claim 14, comprising an anti-CD20 VL region comprising SEQ ID NO: 323 and a VH region comprising SEQ ID NO:
324.
16. 16. The bispecific antibody of claim 15, comprising an anti-CD20 LC region comprising SEQ ID NO: 331 and an anti-CD20 HC region comprising SEQ ID NO:
332.
17. 17. The bispecific antibody of claim 16, comprising an LC region of anti-CD47 comprising SEQ ID NO: 385 and an HC region of anti-CD47 comprising SEQ ID NO:
386.
18. 1. A pharmaceutical composition for administration to a patient in need thereof, comprising: i) the bispecific antibody of claim 1; and ii) at least one pharma- ceutically acceptable carrier.
19. The pharmaceutical composition of claim 18, wherein the patient's tumor cells are inhibited.
20. 20. The pharmaceutical composition of claim 19, wherein the patient's hematological malignancy or B cell disorder is inhibited.
21. 21. The pharmaceutical composition of claim 20, wherein the B cell malignancy in the patient is inhibited.
Citation Information
Patent Citations
Tetravalent bispecific antibody
JP2016514676A
sirp-alpha immunoglobulin fusion protein
JP2017525698A
Casting apparatus for the production of a cast web of homogenized tobacco material
JP2018500017A
CD47 antibodies and methods of use thereof
WO2013119714A1
Heterodimeric protein composition
WO2014054804A1
